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The HIV-1 Vpu protein functions largely to target CD4 molecules for proteasomal 
degradation, and to enhance virion release. The subcellular localisation of Vpu is 
related to these functions. Previous studies showed subtype B Vpu localisation at the 
ER/Golgi complex, while subtype C Vpu localised to the plasma membrane (PM) at 
48 hours post-transfection. To determine if subtype C Vpu can localize to the 
ER/Golgi, we evaluated the cellular localisation of Vpu from two South African 
subtype C isolates as compared to subtype B Vpu, over time. Codon optimized vpu 
genes from subtype C isolates FV5 and FV15 (which have a six and two amino acid 
insert in the N-terminal domain, respectively) and a representative subtype B vpu 
were TA cloned into the pcDNA6.2/C-emGFP expression vector. The three Vpu-
emGFP recombinant plasmids were cotransfected with pDsRed-ER, pDsRed-Golgi, 
or pDsRed-Mem into HEK 293T cells, and observed at 24, 48, and 60 hours post-
transfection under a confocal microscope to confirm the presence of Vpu at different 
subcellular compartments. Cotransfection and microscopy conditions were 
methodically optimised. At 24 hours post-transfection, the subtype C FV5 Vpu had 
ER/Golgi localisation, but none at the PM. The subtype C FV15 Vpu had weaker 
ER/Golgi localisation and no PM localisation. In contrast, the subtype B Vpu had 
strong PM localisation. At 48 hours, FV5 and FV15 Vpu showed PM localisation, 
while subtype B Vpu was clearly localised at the ER/Golgi. At 60 hours, FV5 Vpu was 
observed at the PM, whereas FV15 and subtype B Vpu showed ER/Golgi localisation. 
These findings illustrate the efficient translocation of Vpu between different cellular 
compartments and for the first time, the difference in timing between subtype B and C 
Vpu, as well as íntrasubtype differences. This difference in shuttling suggests 
implications for the timing of viral assembly and release. Further investigations may 
clarify the impact of this timing on the difference in disease pathogenesis noted 
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1.1 The Human Immunodeficiency Virus and the global AIDS epidemic 
 
1.1.1 The global AIDS epidemic 
 
The Human Immunodeficiency Virus type 1 (HIV-1) is the causative agent of Acquired 
Immunodeficiency Syndrome (AIDS) (Barre-Sinoussi, Chermann et al. 1983; Blattner, 
Gallo et al. 1988), and is responsible for the pandemic affecting between 30 and 36 
million people worldwide (www.unaids.org 2008). Sub-Saharan Africa is the most 
seriously affected by the HIV pandemic, accounting for 67% of all infections and 72% 
of AIDS deaths in 2007 (www.unaids.org 2008). This number continues to rise 
although the prevalence of HIV in sub-Saharan Africa, currently ranging between 10% 
and 12%, has stabilised due to increased access to antiretroviral therapy (ART) 
(www.unaids.org 2008). Outside Africa, infections are on the rise in a number of 
countries, with global adult HIV prevalence ranging between 3% and 4% 
(www.unaids.org 2008). Despite the benefits of ART and improvements in access to 
therapy, there are approximately three million AIDS-related deaths per year 
worldwide, including an estimated 490 000 children under the age of fifteen 






1.1.2 Classifications of HIV 
 
HIV-1 and the closely related simian immunodeficiency virus (SIV) are classed as 
retroviruses, and belong to the subgroup known as lentiviruses. Retroviruses are 
viruses that contain ribonucleic acid (RNA) genomes, able to reverse transcribe their 
genome into a deoxyribonucleic acid (DNA) copy (cDNA), and thus replicate within 
the host cell nucleus. Primate lentiviruses are grouped into five distinct lineages, 
including HIV-1, HIV-2, and SIVCPZ (Osmanov, Heyward et al. 1995). HIV-1 is divided 
into group M (major), N (non-group M or O) and O (outliers). Group M accounts for 
over 90% of all HIV-1 infections worldwide, and phylogenetic analysis of the envelope 
(env) and core (gag) genes has identified at least eight genetic subtypes (A, B, C, D, 
F, G, H, J, K) (http://www.hiv.lanl.gov/ 2009). Numerous circulating recombinant 
forms (CRFs) also exist within group M and continue to be identified, with a total of  
43 CRFs described to date (http://www.hiv.lanl.gov/ 2009). HIV-1 is considerably 
more virulent than HIV-2, while HIV-1 group M subtype C accounts for over 45% of 
new infections worldwide (Oliveira and Cassol 2009). The reasons for the 
pervasiveness of this subtype are still unknown, but some differences do exist 
between this subtype and others within this group. Notably, syncytia- (CXCR4-tropic) 
and non-syncytia-inducing (CCR5-tropic) subtype C isolates are less fit in peripheral 
blood mononuclear cell (PBMC) competition assays than the nine subtype B isolates 
tested (Ball, Abraha et al. 2003). The replicative fitness of subtype C strains is also 
reduced in PBMCs when compared to other group M isolates, but is still 100 fold 
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higher than HIV-2 or group O isolates (Arien, Abraha et al. 2005; Salim and Ratner 
2008).  
 
1.1.3 Pathogenesis of HIV-1 
 
HIV-1 infection is characterised by a gradual deterioration in immune function and 
ultimately AIDS (Levy 1993). Pathogenesis studies of HIV-1 explore the diverse 
mechanisms that lead to this immune system destruction. Understanding how the 
virus establishes infection is essential to the identification and development of 
effective therapeutics and vaccines. HIV infects cells expressing the surface 
glycoprotein, cluster designation four (CD4) (Lyerly, Matthews et al. 1987). CD4-
positive (CD4+) cells include T-helper lymphocytes and macrophages. Viral tropism is 
determined by the binding of the viral envelope protein (Env, gp120) to its primary 
receptor, CD4, in conjunction with a chemokine co-receptor, CCR5 or CXCR4 
(Dejucq 2000). Cytotoxic T-cells (CD8+ T-cells) and B-cell-produced antibodies act to 
moderate viral levels in acute infection, but the virus persists in the form of escape 
mutants and viral reservoirs (Greene 1993). Infection of follicular dendritic cells, and 
therefore accumulation of virus within lymphoid germinal centers, causes tumour 
necrosis factor alpha (TNFα) and interleukin-six (IL-6) secretions (Schnittman, 
Denning et al. 1990). This in turn initiates T-cell activation allowing further HIV 
dissemination (Ho, Neumann et al. 1995). The lymph node architecture then breaks 
down preventing normal immune system function. Infection eventually leads to 
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depletion of CD4+ T-cells by poorly understood mechanisms (Connor, Mohri et al. 
1993). Speculation around CD4+ T-cell loss includes: direct killing by viral budding 
(Garry 1989), apoptosis of infected and uninfected cells (Ameisen and Capron 1991; 
Laurent-Crawford, Krust et al. 1991; Finkel, Tudor-Williams et al. 1995; Pantaleo and 
Fauci 1995), antibody-dependent cellular cytotoxicity (ADCC) (Ahmad, Yao et al. 
1994), anergy (Sousa, Carneiro et al. 2002), and damage to immune system 
precursor cells (Schnittman, Denning et al. 1990). In due course, severe 
immunosuppression arises, distinguished by idiopathic CD4+ lymphocytopenia (a 
CD4 count of less than 300 cells per mm3 blood) (Aledort, Operskalski et al. 1993; 
Busch, Valinsky et al. 1994). The result is vulnerability to opportunistic infections, with 
AIDS patients typically manifesting infections of the lungs, brain, eyes and intestinal 
tract (www3.niaids.nih.gov 2008).  
 
1.1.4 The structure and life cycle of HIV-1 
 
The replication cycle of HIV involves reverse transcription of the viral RNA, integration 
of the viral cDNA into the host genome, transcription of viral messenger RNA 
(mRNA), and translation of mRNA into viral proteins (Frankel and Young 1998).  
These proteins assemble into progeny virions, before budding from the host cell 
membrane. The final maturation step, involving protease cleavage of specific sites 
within the complete Gag protein, leads to the production of fully infectious virions  
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Figure 1.1: Schematic of the HIV-1 genome. The approximately 9.7 kb genome is comprised of 
three structural genes (gag, pol, env), two regulatory genes (tat, rev), and four accessory genes 
(vif, vpr, vpu, nef). The nine genes are flanked by a 5’ and 3’ LTR regions. The focus of this 
study, Vpu, is outlined. This image was adapted from the HIV Sequence Compendium 2003, 
Landmarks of the HIV-1 genome, page iv (Leitner, Foley et al. 2003). 
 
 
capable of initiating further rounds of infection (Frankel and Young 1998; Schubert, 
Ott et al. 2000). Viral genes act in concert with host cellular machinery to control 
these processes. HIV-1 is a particularly efficient virus, able to perform a multitude of 
functions with a genome comprising of just nine genes (Figure 1.1), encoding at least 
sixteen proteins (http://www.hiv.lanl.gov/ 2009). Three of the nine genes encode 
structural proteins (gag, pol, env), two have regulatory functions (tat, rev), and four 
are dubbed accessory genes (vif, vpr, vpu, nef) (http://www.hiv.lanl.gov/ 2009). The 
accessory genes of HIV are unique in that most other retroviruses only encode the 
env, gag, and pol genes (Hout, Mulcahy et al. 2004). The accessory proteins were 
initially thought to be dispensable for viral replication, but have now been shown to 
function as crucial enhancers of viral pathogenesis. They act as versatile adaptor 
molecules that connect viral and cellular pathways, and lead to efficient viral 










dispensable for replication in vitro, they allow the virus to establish and persist within 
the host. The viral protein U (Vpu) is the smallest of the accessory proteins, and 
performs a central role in viral budding, thus enhancing viral pathogenesis and 
infectivity. 
 
1.2 The Viral Protein U  
 
The Viral Protein U is an oligomeric, type I integral membrane protein of 
approximately 16 kDa (Cohen, Terwilliger et al. 1988). It ranges from 81 to 86 amino 
acids in length depending on the viral subtype (http://www.hiv.lanl.gov/ 2009). It is 
expressed late in the viral life cycle from bicistronic mRNA that also encodes the HIV-
1 envelope glycoprotein, ensuring synchronous expression (Schwartz, Felber et al. 
1990; Bour and Strebel 2003) (Figure 1.2). It is found only in the infected cell and is 
not incorporated into virions (Strebel, Klimkait et al. 1988). Interestingly, this protein is 
a distinguishing characteristic, unique to HIV-1 and the simian strains, SIVcpz and 
SIVgsn (Huet, Cheynier et al. 1990; Courgnaud, Salemi et al. 2002). Vpu is generally 
well conserved in isolates from AIDS patients (Lee, Schwartz et al. 1997), with 
premature stop codons noted in long term non-progressors (LTNPs) (Yamada and 
Iwamoto 2000).  
 
Vpu is a multifunctional protein, whose effect on efficient viral replication and CD4+ T-




Figure 1.2: Overview of the HIV-1 replication cycle highlighting the expression of Vpu. Entry 
involves binding of viral envelope spikes (gp120 in red) to the CD4 receptor on the surface of 
host cells. Conformational changes in gp120 allow for engagement of the coreceptor, CCR5 or 
CXCR4, and fusion via envelope gp41 and internalisation of the viral core. Uncoating of the 
core releases the two single-stranded viral RNAs (ssRNA) for reverse transcription into double-
stranded DNA (dsDNA). Proviral DNA is transported into the cell nucleus and integrated into the 
host chromosomal DNA. Full-length and spliced viral mRNA, as well as progeny virion RNA, are 
transcribed by host polymerases. Viral proteins are translated on the ribosomes of the rough 
endoplasmic reticulum (RER), and processed via the endoplasmic reticulum (ER) and the Golgi 
apparatus. New viral proteins and genomic RNA are assembled into immature virions. The new 
virus particles bud from the cell via the plasma membrane, and become infectious by 
proteolytic cleavage of the entire Gag protein by viral Protease. Vpu acts specifically at the 
ER/Golgi interface to bind newly synthesised CD4 molecules, and at the cell plasma membrane 
to down-regulate the host antiviral proteins, tetherin and Calcium-modulating cyclophilin ligand 
(CAML), and to form cation-specific ion channels. This illustration was adapted from (Greene, 

























biological functions have been identified and unambiguously demonstrated. These 
functions are linked to the protein’s two major structural domains: the transmembrane  
domain (TMD) functions in the enhancement of virion release, and the cytoplasmic 
domain (CD) functions in the degradation of newly synthesized CD4 molecules at the 
endoplasmic reticulum (ER) (Strebel, Klimkait et al. 1988; Maldarelli, Chen et al. 
1993). Lesser-defined roles for Vpu include ion channel activity, the downregulation of 
major histocompatibility complexes (MHC) type I and II, and the induction of 
apoptosis (Hout, Mulcahy et al. 2004). The long held conviction that Vpu overcomes a 
host restriction factor to virion release has recently been confirmed in the guise of the 
newly characterised protein, tetherin (Neil, Zang et al. 2008). Accordingly, Vpu 
contributes to viral pathogenesis by overcoming this newly identified antagonist to 
virus release. 
 
1.2.1 Vpu structural characteristics 
 
The Vpu protein is organised into three domains: a short N-terminal domain (NTD), a 
hydrophobic TMD, and a relatively hydrophilic CD. Interestingly, the NTD of subtype 
C Vpu contains a one to five amino acid insertion accounting for the variation in 
subtype C-protein length. This insertion is absent in all other subtypes and non-
subtype C CRFs (http://www.hiv.lanl.gov/ 2009). The functional relevance of this has 
not yet been investigated. The TMD anchors the protein within host cell membranes 
(Cohen, Terwilliger et al. 1988; Strebel, Klimkait et al. 1988), and it has been well 
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demonstrated to act as a monomer of a pentameric ion channel favouring monovalent 
cations (Lemaitre, Willbold et al. 2006). Pore radius profiles show that a homomeric 
pentamer bundle has the lowest potential energy profile, and molecular modelling 
studies confirm that five Vpu transmembrane (TM) spanning α-helices oligomerize to 
act as an ion-selective channel (Cordes, Kukol et al. 2001; Lemaitre, Ali et al. 2004). 
The TMD is connected to the CD via a highly conserved salt bridge region, 36-
EYRKIL-41 (Figure 1.3). Molecular dynamics simulations show that the glutamate (E) 
is involved in salt bridge formation with the lysine (K) and arginine (R), forming a 
flexible kink between the TMD and CD (Sramala, Lemaitre et al. 2003). The CD is 
therefore free to bind proteins within the cytoplasm. This region contains two 
amphipathic alpha helices (α-helix 1 and 2) flanking an especially conserved motif 
with two crucial serines (S), 58-EDSGNESEG-66 (Figure 1.3) (Willbold, Hoffmann et 
al. 1997). These serines are subject to phosphorylation by casein kinase II (CKII) 
allowing for binding of Vpu to the human host factor, β-transducin repeats-containing 
protein (ßTrCP), an essential step in CD4 proteasomal degradation (Margottin, Bour 
et al. 1998). Alpha-helix two, as well as the C-terminal residues physically interact 
with CD4 (Margottin, Benichou et al. 1996). The concurrent binding of Vpu to CD4 
and ßTrCP results in the degradation of CD4 via the ubiquitin-dependent proteolytic 
apparatus (Terwilliger, Cohen et al. 1989; Willey, Maldarelli et al. 1992; Margottin, 








Figure 1.3: Schematic diagram showing the major structural domains of Vpu and their 
orientation in the cellular membrane. The hydrophobic transmembrane domain inserts into 
cellular membranes, while the hydrophilic cytoplasmic domain is free to bind proteins within 
the cell. The transmembrane domain enhances virion release by oligomerising into ion-
channels, and by binding to tetherin. The crucial serines positioned between the cytoplasmic α-
helices, are phosphorylated (in red) by casein kinase II, and allow for the binding of ßTrCP and 
CD4. This leads to the ubiquitination and degradation of CD4 via the E3-ligase complex. This 
















1.2.2 Vpu functional characteristics 
 
Vpu interacts with a diverse range of host proteins to perform its function 
(summarized in Table 1.1). The structural domains of Vpu are linked to its role in the 
viral life cycle. Studies on the Vpu protein from laboratory-adapted subtype B virus 
have shown that the TMD functions in enhancing virion release, and the CD is 
involved in CD4 degradation (Terwilliger, Cohen et al. 1989; Klimkait, Strebel et al. 
1990; Willey, Maldarelli et al. 1992; Montal 2003). The trafficking and subcellular 
localization of Vpu is related to these functions. Its presence at the rough 
endoplasmic reticulum (RER)/trans-Golgi network (TGN) is linked to its ability to 
down-modulate CD4, while its presence at the plasma membrane (PM) is correlated 
to its ability to enhance virion release. A Vpu-enhanced green fluorescent protein 
(EGFP) construct showed subcellular localization of subtype B Vpu predominantly to 
the ER/Golgi complex, while subtype C Vpu was more efficiently transported to the 
plasma membrane (PM) at 48 hours post transfection (Pacyniak, Gomez et al. 2005). 
Further experiments with chimeric subtype B/C Vpu proteins where the CD regions 
were exchanged, determined that the difference in localisation was a factor of the 
second α-helical region of the CD (Pacyniak, Gomez et al. 2005). Subtype B Vpu-
retention at the Golgi was accordingly narrowed down to carboxyl 13-23 amino acids 
(Pacyniak, Gomez et al. 2005).  
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Golgi proteins have tyrosine-, dileucine-, or phenylalanine-based retention or retrieval 
signals. Subtype C Vpu has two of these dileucine-based motifs (RKLL and LRLL), 
as well as another potential CKII site (TMVD). Notably, LRLL and TMVD both reside 
in the carboxy-terminal of the protein. The overlapping tyrosine-based (YXXф) and 
dileucine-based ([D/E]XXXL[L/I]) motifs in the salt bridge region of subtype C Vpu 
were found to be involved in the trafficking of Vpu (Ruiz, Hill et al. 2008). It was 
concluded that this membrane proximal, cytoplasmic, tyrosine-based motif is 
essential for efficient virus release, and that the dileucine motif is a sorting signal 
affecting the intracellular trafficking, cytopathology and the enhanced release function 
of subtype C Vpu (Ruiz, Hill et al. 2008). Interestingly, both subtype B and C Vpu 
were functional for CD4 down-modulation in these experiments (Pacyniak, Gomez et 
al. 2005). The ability of subtype C Vpu to down-modulate CD4 in its apparent 
absence in the ER/Golgi complex poses numerous questions that require further 
investigation.  
 
1.3 CD4 downregulation 
 
CD4 is a type I transmembrane glycoprotein that functions, along with the T-cell 
antigen receptor (TCR), to recognise antigens presented by the MHC II molecules on 
antigen presenting cells (APCs) (Bowers, Pitcher et al. 1997). The adaptive immune 
response requires CD4+ T-cells to initiate B-cell and CD8+ T-cell differentiation 
(Bowers, Pitcher et al. 1997).  
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Table 1.1: Overview of all HIV-1 Vpu and human protein interactions cited in the HIV-1, Human 
protein Interaction database* (www.ncbi.nm.nih.gov; last updated in November 2007) (Ptak, Fu 
et al. 2008; Fu, Sanders-Beer et al. 2009; Pinney, Dickerson et al. 2009), including the newly 
described interactions with tetherin (Neil, Sandrin et al. 2007) and CAML (Varthakavi, Heimann-
Nichols et al. 2008).   
 
Interaction Protein 
Activates Caspase 3 preproprotein 
ßTrCP isoform 2 
Antagonises Tetherin/CD137/BST-2/HM1.24 
CAML 
Degrades CD4 antigen precursor 
Downregulates BCL2-like isoforms 1 
BCL2-related protein A1 
CD4 antigen precursor 
MHC 1, A precursor 
MHC 1, B  
MHC 1, C precursor 
TNF receptor-associated factor 1 
Inhibited by CD4 antigen precursor 
Inhibits ßTrCP isoform 2 
NFKß, subunit 1 
Interacts with FBXW11: F-box and WD-40 domain protein 11; 
ßTrCP 2 
Potassium channel, subfamily K, member 3 
Small glutamine-rich tetratricopeptide 
TNF-receptor superfamily, member 6, isoform 1 
precursor 
Phosphorylated by CK 2, α-prime polypeptide 
CK 2, ß-polypeptide 
CK 2, α-1 subunit isoform A 
Recruits ßTrCP isoform 2 
Regulates CD4 antigen precursor 
Upregulates CD40 isoform 1 precursor 
Vascular cell adhesion molecule 1 isoform a 
preursor 
Stabilizes ATF4 
Catenin (cadherin-associated protein), beta 1, 88 
kDa 
NFκ light polypeptide gene enhancer in B-cells 
inhibitor, alpha 
*For individual references, refer to the website, or within the text.  
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This process depends on the recognition by CD4+ T-cells of antigens presented on 
the surface of APCs by MHC II α and ß chains (Bowers, Pitcher et al. 1997). CD4 
binds to the Lck non-receptor tyrosine kinase via its cytoplasmic tail, before trafficking 
together along the biosynthetic pathway to the plasma membrane (Bijlmakers and 
Marsh 1999). These proteins remain a stable complex by interaction with an APC, 
allowing contact with the TCR and consequently T-cell activation (Bowers, Pitcher et 
al. 1997). CD4 is also found in small amounts on all endomembranous systems. 
These include the endocytic, lysosomal, and secretory pathways (Bour, Schubert et 
al. 1995) 
 
This ubiquitous nature of CD4 poses several problems for HIV-1 replication. CD4 
binds the Env precursor, gp160 at the TGN, effectively preventing protease 
processing of the viral protein, and its trafficking to the PM (Willey, Maldarelli et al. 
1992). There is also a degree of CD4-retention within the budding virion, impeding 
normal virion function (Cortes, Wong-Staal et al. 1998). The presence of CD4 on the 
cell surface also contributes to superinfection, a state that results in an increase in 
cytopathic effects on host cells. Protection against superinfection is speculated to 
decrease apoptosis caused by accumulated, un-integrated viral DNA (Daniel, Katz et 
al. 1999), and to slow the rate of viral recombination (Lama 2003). CD4 down-
modulation thus enhances viral release and infectivity (Cortes, Wong-Staal et al. 
1998; Bour, Perrin et al. 1999). Since CD4 interacts with MHC II on APCs, and a vital 
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co-stimulatory factor of TCR-mediated T-cell activation, down-modulation may also 
reduce the host’s antiviral response (Wildum, Schindler et al. 2006). 
 
The virus has therefore developed multiple and redundant mechanisms to down-
modulate CD4 and in so doing enhance pathogenesis. HIV-1 CD4 downregulation is 
carried out through the actions of Nef, Vpu, and to a lesser extent, Env (Wildum, 
Schindler et al. 2006). Nef is expressed early in the viral lifecycle, and downregulates 
CD4 at the cell surface with subsequent lysosomal degradation (Aiken, Konner et al. 
1994; Craig, Pandori et al. 1998). In contrast, both Env and Vpu are expressed later, 
and are involved in preventing the transport of de novo synthesized CD4 molecules to 
the cell surface, as well as the targeting of CD4 molecules for ubiquitin-dependent 
proteasomal degradation at the RER (Willey, Maldarelli et al. 1992; Geleziunas, Bour 
et al. 1994; Montal 2003).  
 
Vpu specifically functions early in the secretory pathway by binding to the cytoplasmic 
tail of CD4 via its CD α-helices (Bour, Schubert et al. 1995; Tiganos, Yao et al. 1997). 
The host cell factor, ßTrCP is thus recruited to the ER membrane (Margottin, Bour et 
al. 1998). This action depends on the phosphorylation of the two crucial serines in the 
Vpu CD by CK II (Schubert, Henklein et al. 1994), and its subsequent binding to the 
WD-repeat domain of ßTrCP (Tiganos, Yao et al. 1997). ßTrCP then mediates the 
docking of the Skp I-Cullin-F-box (SCF) complex and transferal of ubiquitin to the 
cytoplasmic tail of CD4 (Margottin, Bour et al. 1998). This action adapts CD4 to the 
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E3 ubiquitin ligase complex, resulting in the proteasomal degradation of CD4 and the 
subsequent release of gp160 (Bai, Sen et al. 1996; Margottin, Bour et al. 1998) 
(Figure 1.4). Thus, gp160 is released for processing into gp120 and gp41, proteins 
necessary in large amounts for virion assembly. Remarkably, Vpu itself, unlike other 
ßTrCP-interacting proteins, is not targeted for degradation by proteasomes 
(Lindwasser, Chaudhuri et al. 2007). This process resembles the ER-associated 
degradation (ERAD) pathway, which recognises and clears misfolded proteins and 
unassembled protein subunits from the ER (Meusser and Sommer 2004).  
 
1.4  Enhancement of virion release 
 
Vpu is involved in the detachment of newly assembled HIV-1 virions from the cell 
surface. Several mechanisms of Vpu-mediated release are apparent (Figure 1.4). 
First, Vpu is able to direct cation-specific channel activity via its TMD, scrambling of 
which abolishes its ability to increase membrane conductance and virion release 
(Schubert, Ferrer-Montiel et al. 1996). Secondly, Vpu is also able to interact with a 
number of host factors that act normally to inhibit virus budding. Initially these proteins 
were identified as the TWIK-related acid-sensitive potassium channel 1 (TASK-1) 
(Hsu, Seharaseyon et al. 2004), and the Vpu binding protein (UBP) (Handley, 
Paddock et al. 2001). More recently however, tetherin (also known as bone marrow 
stromal cell antigen 2 or BST-2, HM1.24 and CD317) (Neil, Zang et al. 2008) and 
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calcium-modulating cyclophilin ligand (CAML) (Varthakavi, Heimann-Nichols et al. 
2008) have been identified (detailed in section 1.5).  
 
The Vpu TM domain directs weak ion-selective channel formation, possibly modifying 
the micro-environment to enhance virion release from infected cells (Lakos, Somogyi 
et al. 1990). Protein oligomerization results in hydrophilic pores at the membranes of 
virus-infected cells (Gonzalez and Carrasco 1998). Hence, virion release may be 
influenced by changes in host cell membrane protein conformation, membrane 
fluidity, and ion homeostasis (Gonzalez and Carrasco 1998; Gonzalez and Carrasco 
2001). Viral ion channels, or viroporins, are characteristic of enveloped viruses, and 
are formed by the proteins of influenza A (M2 protein), influenza B (NB protein), 
influenza C (CM2 protein), poliovirus (2B protein), Sindbis virus (6K protein) and more 
recently, the Paramecium bursaria chlorella virus and the hepatitis C virus (p7 
protein) (Fischer and Sansom 2002; Premkumar, Wilson et al. 2004). The E protein 
from the Severe Acute Respiratory Syndrome (SARS) coronavirus is also able to 
fashion cation-selective ion channels in lipid bilayers (Wilson, Gage et al. 2006).  
 
Viroporins are all associated with membrane permeability, influencing viral entry, 
glycoprotein trafficking, replication, and budding (Ciampor 2003; Gonzalez and 
Carrasco 2003). Vpu specifically interacts with TASK-1 ion channel via the first 40 
amino acids of TASK-1 that are also homologous to Vpu (Hsu, Seharaseyon et al. 
2004; Strebel 2004). Vpu is able to abolish TASK-1 current, while overexpressing 
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TASK impairs Vpu-enhanced viral particle release (Hsu, Seharaseyon et al. 2004). 
This suggests Vpu may have evolved from this mammalian protein, and has hijacked 
its function. Conspicuously, viroporins form a target for amiloride analogues, 
traditionally used as antivirals and to inhibit calcium channel blockers (Garcia, King et 
al. 1990). The Vpu TM domain is targeted by the amiloride derivatives, 5-(N,N-
hexamethylene)amiloride and 5-(N,N-dimethyl)amiloride, but not by amiloride or 
amantadine itself (Ewart, Mills et al. 2002). This ability of a variety of enveloped 
viruses to form ion channels suggests its importance in the viral life cycle, and 
advocates the effectiveness of amiloride derivatives as potential anti-HIV agents 
(Premkumar, Wilson et al. 2004). 
 
Vpu stimulates the release of an array of retrovirus particles from cells. This list 
includes cells infected by murine leukaemia virus (MLV), equine infectious anaemia 
virus (EIAV), Visna virus, as well as virus-like particles based on the structure of the 
Ebola virus (Neil, Sandrin et al. 2007). The integrity of the Vpu TMD is essential for 
progeny virus release (Tiganos, Friborg et al. 1998), with budding structures 
accumulating and unable to detach from the cell surface in the absence of Vpu 
(Klimkait, Strebel et al. 1990). This accumulation of virions, observed by electron 
microscopy, is the result of endocytic uptake of nascent particles from the cell surface 
in CD63+ endosomes (Neil, Eastman et al. 2006; Neil, Sandrin et al. 2007). In the 
event that internalisation is blocked, virions form characteristic tethers at the cell 
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surface, and these chains can be released by protease treatment (Neil, Eastman et 
al. 2006). 
 
This mechanism of Vpu-enhanced virus release is distinct from Endosomal Sorting 
Complex Required for Transport (ESCRT)-Gag interaction that allows for interaction 
with proteins involved in sorting via multivesicular bodies (MVBs) (Schwartz, 
Geraghty et al. 1996; Neil, Eastman et al. 2006). Alternatively, Vpu is involved in 
interactions with the pericentriolar recycling endosome (Vasundhara 2006). Vpu 
inhibits the internalisation of Env and Gag into late endosomes, leading to viral 
assembly at the PM (Van Damme and Guatelli 2008). Vpu colocalises with markers 
for  the pericentriolar recycling endosome, and must exit this compartment to exert its 
effect (Varthakavi, Smith et al. 2006). Disruption of protein sorting by the recycling 
endosome, using Rab11a and myosin Vb mutants, inhibits Vpu particle release 
(Varthakavi, Smith et al. 2006). Vpu therefore facilitates the amassing of Gag at the 
PM, allowing virion assembly (Neil, Eastman et al. 2006).  
 
Vpu-mediated virus detachment is also cell-type-dependent and species specific 
(Sakai, Tokunaga et al. 1995; Jouvenet, Neil et al. 2009; McNatt, Zang et al. 2009). It 
is required for efficient virion release in non-permissive cells, such as HeLa cells 
(Strebel, Klimkait et al. 1989; Terwilliger, Cohen et al. 1989; Klimkait, Strebel et al. 
1990; Gottlinger, Dorfman et al. 1993). Permissive cells, however, do not need Vpu 
for effective virion release, and include the African green monkey (AGM) cell line, 
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COS-7 (Geraghty, Talbot et al. 1994; Neil, Eastman et al. 2006). Remarkably, tetherin 
proteins from old world monkey species (AGMs and rhesus macaques), and from 
mice, inhibit HIV-1 release, but are resistant to Vpu (McNatt, Zang et al. 2009). Thus, 
viral antagonists may have driven the selection of the tetherin variants that exist in 
chimpanzees and humans (McNatt, Zang et al. 2009).  
 
Vpu may also function to enhance virus release by causing the dissociation of Gag-
UBP complexes and the redistribution of Gag to the cell periphery (Callahan, Handley 
et al. 1998; Handley, Paddock et al. 2001). UBP is a member of the tetratricopeptide 
repeat (TPR) protein family (Chen, McPartlin et al. 1994). These proteins play diverse 
roles including organelle targeting, mitosis, immunophilin-, and phosphatase-protein 
activity (Hase, Riezman et al. 1983; Sikorski, Boguski et al. 1990; Ratajczak, Carrello 
et al. 1993; Chen, McPartlin et al. 1994). Importantly, UBP also interacts with HIV-1 
Gag, and its overexpression results in a reduction in virus release (Handley, Paddock 
et al. 2001). This state is rescued by the co-expression of Vpu, which causes Gag-
UBP dissociation and renders Gag unable to rebind to UBP, allowing Gag to move to 
the PM (Callahan, Handley et al. 1998).  
 
Taken together, this evidence suggests that Vpu antagonises a host cell restriction 
factor that acts non-specifically to disrupt HIV-1 particle release in some human but 
not simian cells (Varthakavi, Smith et al. 2003). This function may in turn be related to 
its facility for ion channel formation. The pericentriolar endosome represents a 
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possible site for host restriction factor interaction (Varthakavi, Smith et al. 2006). This 
host cell factor was initially proposed to be the background ion channel, TASK-1 
(Hsu, Seharaseyon et al. 2004), or the Gag-binding protein, UBP (Handley, Paddock 
et al. 2001). Recently, though, the novel host-restriction factor, tetherin has been 
shown to antagonise the budding of virus particles by causing the internalisation from 
and accumulation of virions at the cell surface (Neil, Zang et al. 2008). Accordingly, 
Vpu may enhance virion release by blocking tetherin activity. 
 




Vpu blocks the accumulation of virions in intracellular vacuoles at the PM, allowing  
viral budding (Klimkait, Strebel et al. 1990). The factor that causes this accumulation 
of virions was concluded to act after virion assembly, at the cell surface, and to 
induce virion internalisation. The requirement for Vpu is also enhanced by the 
treatment with interferon-α (IFN-α) (Neil, Sandrin et al. 2007). Neil et al. therefore 
concluded that the inhibitor of retrovirus release is an IFN-α-induced, cell surface 
protein (Neil, Sandrin et al. 2007; Neil, Zang et al. 2008). They identified this protein 
by microarray analyses of mRNAs expressed by untreated and IFN-α-treated 
permissive and non-permissive cells (Neil, Zang et al. 2008). Tetherin/CD137/BST-
2/HM1.24 was identified and confirmed by transfection of these cells with wild-type 
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Figure 1.4: Schematic representation of the functions of Vpu within the infected cell. Vpu acts late in 
the viral life cycle to bind newly synthesised CD4 at the ER/Golgi interface. Concurrent binding to 
ßTrCP adapts CD4 to the E3-ligase complex causing the ubiquitination and subsequent degradation of 
CD4 in the proteasome. This process effectively releases bound gp160 from CD4 and allows for gp160 
to traffic to the cell membrane to act in virion assembly. Vpu also traffics to the cell surface to function 
in enhancing virion release. In the absence of Vpu, virus particles are tethered at the cell surface in the 
form of long chains, and then internalised into early endosomes via TSG101/tetherin/CAML. The 
trapped virions are then transported to lysosomes where they are digested. Vpu binds tetherin via its 
TM domain and prevents the accumulation of virions at the cell surface. Vpu also prevents the 
































(Gag association with 
tetherin/CAML/TSG101)
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and Vpu-deleted (delVpu) HIV-1 proviral plasmids (Neil, Zang et al. 2008; Van 
Damme, Goff et al. 2008). Single-cycle HIV-1 replication assays in CD4-negative cells 
expressing CD137 constitutively, showed >100 fold reduction in delVpu virion yield 
(Neil, Zang et al. 2008). Viral Gag expression in infected cells remained unchanged in 
the absence or presence of tetherin demonstrating that viral assembly remains 
unaltered and tetherin acts only at the level of viral release (Neil, Zang et al. 2008). 
Short interfering RNA (siRNA) targeted against tetherin also enhances the yield of 
delVpu virions from HIV-1 infected cells (Neil, Sandrin et al. 2007).  
 
Tetherin colocalised with Vpu, and in the absence of Vpu, virions were associated 
with tetherin at the cell surface and in endosomes (Neil, Sandrin et al. 2007). Notably, 
tetherin has a complex glycosylation pattern, a N-terminal TM anchor, as well as a C-
terminal glycosyl phosphatidylinositol (GPI) membrane anchor (Kupzig 2003). It is 
able to localise to multiple membrane compartments and removal of this GPI anchor 
eradicates its ability to inhibit delVpu virion release, suggesting that this anchor allows 
the protein to retain nascent virions (Neil, Zang et al. 2008). Tetherin is therefore 
likely to localise to cholesterol-rich domains in the PM, where it may encounter 
assembling retrovirus particles (Kupzig 2003).  
 
Miyagi et al. analysed endogenous tetherin and virus release in HeLa cells, T-cells 
and macrophages (Miyagi, Andrew et al. 2009). This group showed that while Vpu 
reduces tetherin expression in transfected HeLa cells, and infected macrophages, it 
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does not decrease cell surface tetherin levels in CEMx174 and H9 T-cells (Miyagi, 
Andrew et al. 2009). Efficient HIV-1 replication in these cell lines does require Vpu, 
however. Also, tetherin was not present in virions physically sheared from the cell 
surface (Miyagi, Andrew et al. 2009). Overall, this suggests that the Vpu-tetherin 
interaction is not the only function required for virion release.  
 
1.5.2 Calcium Modulating Cyclophilin Ligand 
 
An additional host restriction factor, CAML was also identified recently by another 
group (Varthakavi, Heimann-Nichols et al. 2008). CAML is a cyclophilin B-binding 
integral membrane protein with a vital role in the survival of developing T cells, and 
for the regulation of TCR-activated tyrosine kinase p56Lck (Bram and Crabtree 1994; 
Tran 2005). Notably, it is required for recycling of epidermal growth factor receptor 
(EGFR) to the PM (Tran, Russell et al. 2003). In the absence of Vpu, simian cells 
expressing CAML accumulated virions at the cell membrane. Varthakavi et al. 
revealed that Vpu and Env rescued delVpu-virion release, and depletion of CAML by 
targeted interfering RNA eliminated the need for Vpu to elicit HIV-1 and MLV virion 
release (Varthakavi, Heimann-Nichols et al. 2008).  
 
CAML was identified by yeast two-hybrid screening of human HeLa cell DNA using 
full-length codon-optimised Vpu as bait. The hydrophilic N-terminus of human CAML 
(using truncated recombinant CAMLs) was sufficient for Vpu interaction, confirmed by 
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co-immunoprecipitation experiments using antibodies to endogenous CAML in human 
cells (Varthakavi, Heimann-Nichols et al. 2008). Colocalisation experiments showed 
significant overlapping fluorescence at the perinuclear region, with lesser amounts on 
peripheral vesicular structures. CAML elicits the characteristic delVpu phenotype in 
HIV-1 infected cells of accumulated and tethered virions that is recovered by protease 
treatment (Varthakavi, Smith et al. 2003; Varthakavi, Heimann-Nichols et al. 2008).  
 
HIV-1 Vpu was concluded to offset the block to particle release mediated by CAML by 
a hitherto unknown mechanism. The authors contemplate the role of CAML in EGFR 
recycling and whether it interacts with Vpu along the endosomal recycling pathway 
(Varthakavi, Heimann-Nichols et al. 2008). Vpu may prevent CAML from reaching the 
cell surface, and this may in turn alter the surface expression of the newly described 
protein, tetherin.  
 
1.6 Additional functions of Vpu 
 
1.6.1 Downregulation of the major histocompatibility complex class I and II 
 
Nef acts early in the HIV-1 viral life cycle by promoting the endocytosis of MHC I from 
the surface of APCs, while Vpu acts later to interfere with MHC I heavy chain 
synthesis retaining them at the ER (Schwartz, Marechal et al. 1996; Kerkau, Bacik et 
al. 1997). Yeast two-hybrid assays and co-immunoprecipitation experiments confirm 
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the interaction of Vpu with MHC II invariant chains, or CD74 (Hussain, Wesley et al. 
2008). CD74 is a type II transmembrane protein that binds the α and ß chains of MHC 
II in the ER (Becker-Herman, Arie et al. 2005). Peptide loading of MHC II occurs in 
the Golgi by displacement of the class II-associated Ii peptide (CLIP) domain of CD74 
(Ploegh 1998). This is followed by antigen presentation at the cell surface. CD74 is 
also expressed as a trimer on the cell membrane where it mediates signalling initiated 
by the macrophage inhibitory factor (MIF, also known as macrophage migration 
inhibitory factor; glycosylation-inhibiting factor; phenylpyruvate tautomerase) (Leng, 
Metz et al. 2003). The interaction between HIV-1 Vpu and CD74 occurs specifically 
between α-helix 1 of Vpu and the 30 amino acid C-terminal of CD74 (Hussain, 
Wesley et al. 2008). The surface expression of mature MHC II was observed to be 
downregulated in human monocytic U937 cells transfected with delVpu constructs, 
and this correlated to decreased Ova peptide antigen presentation to Ova-specific 
MHC II restricted-T cells (Hussain, Wesley et al. 2008).  
 
Natural killer (NK) cells are able to kill virus-infected cells where MHC I is 
downregulated (reviewed in (Fauci, Mavilio et al. 2005). Interestingly, Env, Pol, and 
Vpu stimulate the NK cell-mediated ADCC response  (Stratov, Chung et al. 2008). 
This study used overlapping peptides to detect HIV-specific NK cell-recognition 
responses (Stratov, Chung et al. 2008). Vpu-specific interferon-gamma (IFNγ) 
expression by the non-T cell immune response was observed (Stratov, Chung et al. 
2008). Epitope mapping demonstrated that this response was directed against the 
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Vpu CD sequence EMGHHAPWDVD in subtype B, and that the C-terminal aspartic 
acid residues (highlighted) were essential for this response (Stratov, Chung et al. 
2008).  
 
1.6.2 Induction of tumour formation and apoptosis  
 
Vpu acts as a strong competitive inhibitor of βTrCP, impairing the proteasomal 
degradation of cellular SCF-βTrCP substrates (Orian, Gonen et al. 2000). βTrCP is 
redistributed to the cytoplasm from the nucleus in the presence of full-length Vpu, 
resulting in the cytoplasmic accumulation of βTrCP substrates (Besnard-Guerin, 
Belaidouni et al. 2004). These substrates include β-catenin, the inhibitor of nuclear 
factor of kappa light polypeptide gene enhancer in B-cells inhibitor alpha (IκBα),  and 
Activating Transcription Factor 4 (ATF4, also known as tax-responsive enhancer 
element B67) (Besnard-Guerin, Belaidouni et al. 2004; Salim and Ratner 2008) 
(Table 1.1). These proteins play a role in innate immunity, cancer and several 
autoimmune disorders (Li 2000). Vpu may therefore contribute to tumour formation in 
AIDS patients, an opinion underscored by the high levels of β-catenin found in 
Kaposi’s sarcoma (Locher, Fujimura et al. 2003). Notably, β-catenin also promotes 
the maturation of thymocytes, implicating Vpu in the renewal of CD4+ T-cells, and the 
maintenance of the viral life cycle (Gounari, Aifantis et al. 2001).  
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This inhibition of IκBα degradation, in the presence of TNFα, suppresses nuclear 
factor kappa B (NFκB) activity (Bour, Perrin et al. 2001). This in turn sensitizes cells 
to Fas-mediated apoptosis (Akari, Bour et al. 2001). Vpu-induced apoptosis is specific 
and independent of other viral proteins and depends upon Vpu-βTrCP binding (Akari, 
Bour et al. 2001). Vpu also reduces the levels NFκB-dependent anti-apoptotic 
proteins, Bcl-xL, A1/Bfl-1, and TNF receptor-associated factor I (TRAF I) (Akari, Bour 
et al. 2001). Moreover, caspase-3 levels are increased, promoting caspase-mediated 
apoptosis (Akari, Bour et al. 2001). 
 
1.7   Biological relevance of HIV-1 Vpu 
 
1.7.1 Simian-Human Immunodeficiency Virus (SHIV)/Macaque models 
 
Information in the literature regarding Vpu function in vivo is limited but SIV/HIV-1 
(SHIV) chimeric viruses that are able to infect monkeys offer a useful model. Studies 
of monkeys infected with pathogenic SHIV provide the strongest evidence for the role 
of Vpu in HIV-1 pathogenesis (Li, Halloran et al. 1995). Vpu is definitively required for 
pathogenicity in infected macaques (Mackay, Niu et al. 2002), and CD4 down-
regulation is crucial for infectivity (Bour, Perrin et al. 1999; Lama, Mangasarian et al. 
1999). Deletion of vpu causes decreased viral loads, while vpu+ SHIV contributes to 
CD4+ T cell loss during infection (Stephens, McCormick et al. 2002). Remarkably, 
SHIV constructs expressing subtype C Vpu had a more gradual rate of CD4+ T-cell 
 30
loss and decreased viral loads following inoculation of macaques, when compared to 
inoculation with a subtype B construct  (Hill, Ruiz et al. 2008). This group also 
inoculated C8166 cells with chimeric SHIV expressing subtype C Vpu proteins with a 
mutated tyrosine and dileucine in the salt bridge region (Ruiz, Hill et al. 2008). The 
SHIV with an altered dileucine motif showed increased replication kinetics and was 
more cytopathic than the parental virus, and the altered tyrosine motif caused a 
decreased rate of replication (Ruiz, Hill et al. 2008). 
 
1.7.2 CD4 down modulation by Vpu and pathogenesis  
 
The down-modulation of CD4 is crucial for the pathogenesis of HIV-1. CD4 interacts 
with MHC II on APCs and is a costimulatory factor of TCR-mediated T-cell activation 
(Weiss and Littman 1994). CD4 down-modulation also enhances the release and 
infectivity of HIV-1 particles (Bour, Perrin et al. 1999; Lama, Mangasarian et al. 1999; 
Levesque, Zhao et al. 2003). The virus must counteract the effects of CD4 to prevent 
its accumulation in the budding virion and the result of superinfection. High levels of 
CD4 on the surface of HIV-1 infected cells reduces the infectivity of released virions 
by the sequestering of the viral envelope by CD4 (Lama, Mangasarian et al. 1999). 
HIV-1 is also able to prevent superinfection by Vpu-mediated down-modulation of 
CD4 at the ER. As discussed, superinfection is an immune state that leads to 
enhanced levels of apoptosis and viral recombination. Decreasing CD4 may thus 
reduce cell killing, enhance viral spread and reduce frequency of viral recombination 
 31
(Lama 2003). Recombination is beneficial to escape the host immune response, but 
hypothetically detrimental late in the life cycle as it promotes cell death reducing the 
time for productive virion assembly and release (Lama 2003). Vpu-induced 
downregulation of MHC I and II molecules also plays a role in the pathogenesis of 
HIV-1 by contributing to the inability of CD8+ T-cells to eradicate the virus from 
infected individuals (Hussain, Wesley et al. 2008).  
 
1.8 Vpu as a therapeutic target  
 
Overall, this multifunctional protein represents an attractive target for therapeutic and 
preventative interventions. However, there are currently no drugs targeting Vpu in 
human clinical trials. Some options do present themselves. Investigators have shown 
that derivatives of the Na+-K+ antiporter amilorides can prevent Vpu-mediated virion 
release (Ewart, Nasr et al. 2004). Further, the Vpu-ßTrCP binding motif appears to be 
unique, presenting a distinctive point for binding of a small molecule (Lindwasser, 
Chaudhuri et al. 2007). Such an inhibitor may reduce Vpu-induced CD4 degradation, 
allowing CD4 to bind and retain gp160. Vpu-tetherin also represents an attractive 
complex to target. Tetherin forms part of the bone marrow stromal cell factors that are 
involved in the development of B cells (Ishikawa, Kaisho et al. 1995). The specific 
function of human tetherin/BST-2 in uninfected individuals has yet to be resolved. 
Speculation involves a role in pre-B-cell growth, and possibly rheumatoid arthritis 
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(Kupzig 2003). An antiviral agent would need to target specific contact points between 
the TMD of Vpu and tetherin to avoid further immune system dysfunction.  
 
1.9  Rationale for the study 
 
Structure/function studies of the vpu gene have focused on laboratory-adapted 
subtype B isolates, with limited studies detailing the biological characteristics of 
subtype C vpu (Scriba 2001). HIV-1 subtype C represents over 56% of all new HIV-1 
infections worldwide, and predominates in countries of East Africa, Southern Africa, 
India, and Brazil. Of particular interest, HIV-1 subtype C is the predominant subtype 
circulating within the heterosexual population of South Africa (van Harmelen, 
Williamson et al. 2001). The relative worldwide pervasiveness of this subtype points 
to an enhanced ability to evade the host immune response and establish infection. 
Vpu modulates a diverse range of host cell processes, and may therefore influence 
the increased viral infectivity observed in subtype C isolates at multiple levels. Thus, 
further biological characterization is required as a first step in understanding Vpu’s 
contribution to HIV-1 subtype C pathogenesis, particularly with respect to its ability to 
down-modulate CD4 expression. We hypothesise that the South African subtype C 
Vpu will behave similarly to the previously characterised Indian subtype C Vpu 
(Pacyniak, Gomez et al. 2005). A greater understanding of the underlying 
mechanisms of HIV-1 subtype C pathogenesis will allow for a more rational approach 
to designing novel antiviral drugs. 
 33
 
Previous work has described the genotypic characterisation of vif, vpr and vpu from 
20 primary HIV-1 isolates available in our laboratory, and extensive analysis and 
comparison of known functional motifs (Bell, Connell et al. 2007). This study aims to 
determine the subcellular localization of selected South African HIV-1 subtype C Vpu 
proteins over time, as compared to subtype B Vpu. Two subtype C isolates were 
selected based on differences in their overall length, with 05ZAFV5 and 05ZAFV15 
containing a six and two amino acid insertion in the N terminal domain, respectively.  
 
Specific Study objectives: 
 
1. To construct vectors expressing codon-optimized HIV-1 subtype B and C 
Vphu-emGFP fusion proteins. 
 
2. To determine the subcellular localisation of the subtype B and C Vphu-emGFP 
constructs in HEK 293T cells cotransfected with pDsRed-ER, pDsRed-Mem, 
and pDsRed-Golgi markers (Living Colors® Reef Coral Fluorescent Proteins, 







Materials and methods 
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2.1 Viral isolates and plasmids used in this study 
 
2.1.1 Viral isolate selection 
 
A comparison of the predicted amino acid sequences derived from twenty primary 
viral isolates available in our laboratory lead to the selection of the two subtype C 
isolates used in this study (Bell, Connell et al. 2007). The two isolates, 05ZAFV5 and 
05ZAFV15, were chosen based on their predicted Vpu protein length and the 
presence of conserved and significant sequence motifs. No ethics clearance was 
required for this study (Appendix A) as viral isolates were obtained from a previously 




The plasmids described below were used as template, cloning, or expression vectors. 
Plasmid maps are outlined in Appendix B. 
 
2.1.2.1 pcDNA-Vphu and pcDNA™6.2/C-emGFP-GW/TOPO® mammalian 
expression vectors 
 
The codon-optimised pcDNA-Vphu vector (5779 bp) encodes the Vphu protein from 
the HIV-1 subtype B strain, NL4-3 under the constitutive control of a cytomegalovirus 
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(CMV) promoter in a pcDNA3.1 (-) backbone (Nguyen 2004). Two microlitres of 1 
µg/µl plasmid was used to transform competent E. coli cells and to make glycerol cell 
stocks, as described in section 2.2.6 below. This vector was used as a template to 
PCR amplify the vphu gene for subcloning into the pcDNA™6.2/C-emGFP-
GW/TOPO® mammalian expression vector (Vivid Colors™, Invitrogen, Carlsbad, 
CA). This subtype B Vpu expressing plasmid was used as a positive control in all 
experiments. 
 
The pcDNA™6.2/C-emGFP-GW/TOPO® mammalian expression vector (5814 bp)  
from the Vivid Colors™ pcDNA™6.2/C-emGFP-GW/TOPO® Kit (Invitrogen) was 
used for cloning the subtype B and C codon optimised vphu  in frame with the 
emerald green fluorescent protein (emGFP) (Zhang G 1996; Tsien 1998). This vector 
contains a CMV immediate-early (IE) promoter for strong constitutive gene 
expression, as well as a thymidine-adenosine (TA) cloning site. It is provided 
linearised, with a single 3’ thymidine overhang, as well as a covalently bound 
topoisomerase enzyme for TA cloning. An ampicillin resistance gene allows for 
selection of positive clones in E. coli. The positive control vector, pcDNA™6.2/C-
emGFP/GW/CAT (6471 bp), allows for the expression of C-terminally emGFP-tagged 
chloramphenicol acetyltransferase (CAT). This vector was employed as an 
expression control in transfection experiments.  
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2.1.2.2 pDsRed-ER, pDsRed-Mem, and pDsRed-Golgi subcellular 
localisation vectors 
 
The three subcellular marker plasmids, pDsRed-ER, pDsRed-Mem, and pDsRed-
Golgi (Living Colors® Reef Coral Fluorescent Proteins, Clontech Laboratories, Inc., 
Mountain View, CA) were used in cotransfections of mammalian cells with the pVphu-
emGFP vectors. This allowed for the visualisation of requisite organelles, as well as 
the subcellular localisation of the Vphu proteins under investigation. The marker 
plasmids contain the CMV IE promoter, and an upstream Kozak consensus sequence 
to enhance translation efficiency as well as a gene encoding kanamycin resistance in 
E. coli (Clontech Laboratories July 2003). Importantly, they also express the 
monomeric protein, DsRed (Matz 1999) fused to a specific targeting signal peptide. 
The ER-localising vector,  pDsRed-ER encodes the ER targeting sequence of 
calreticulin (Fliegel 1989) fused to the 5’ end of DsRed2 (Matz 1999); and the ER 
retention sequence, KDEL (Munro 1987; Pelham 1996), fused to the 3’ end. The 
Golgi-localising vector, pDsRed-Golgi encodes the N-terminal 81 amino acids of 
human ß-1,4-galactosyltransferase (Watzele 1990), a membrane anchoring signal 
peptide targeting DsRed to the trans-medial region of the Golgi apparatus (Gleeson 
1994; Yamaguchi 1995; llopis 1998). Lastly, pDsRed-Mem encodes the N-terminal 20 
amino acids of neuromodulin (GAP-43) that acts as a palmityolation signal, targeting 
DsRed monomer (Matz 1999) to cellular membranes. Two microlitres of each 1 µg/µl 
plasmid was used to transform competent E. coli cells, cultured in Luria Bertani broth 
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(LB) containing 50 mg/ml kanamycin (Roche Diagnostics, Mannheim, Germany), and 
to make glycerol cell stocks, as described in section 2.2.6 below. 
 
2.2 Construction of Vphu-emGFP for fusion protein expression 
 
2.2.1 Codon optimisation of the native vpu gene 
 
The vpu genes for the selected South African subtype C isolates, 05ZAFV5 and 
05ZAFV15 were codon optimised (Operon Biotechnologies GmbH, Cologne, 
Germany) based on the previously described sequences (Bell, Connell et al. 2007) 
and are encoded by FV5_pCR Script and FV15_pCR Script (Appendix A). Codon 
optimisation adjusts the codon frequency of the foreign protein (namely, HIV-1 Vpu) 
to match the host expression system by changes to secondary structure, GC content 
and repetitive codons (Kyper 1987), allowing for enhanced expression in a 
mammalian system. These genes were designated humanised vpu, or vphu. The 
PCR Script vectors encode for ampicillin resistance for selection of positive clones in 







2.2.2 PCR optimisation 
 
2.2.2.1 Primer design 
 
Polymerase chain reaction (PCR) primers were designed so that the subtype B and C 
vphu genes could be amplified (~300 bp) and directionally cloned into the 
pcDNA™6.2/C-emGFP-GW/TOPO® vector (Invitrogen), in frame with the C-terminal 
emGFP tag. Primer design ensured the inclusion of an upstream Kozak consensus 
sequence for proper initiation and increased efficiency of translation, as well as the 
removal of the native stop codon for cloning in frame with emGFP. Sequence data 
from the FV5_pCR Script and FV15_pCR Script vectors (Operon) provided the basis 
of subtype C vphu PCR primer design. The subtype B vphu gene was sequenced (as 
described in section 2.2.9 below) from the pcDNA-Vphu vector using a T7 primer, and 
the sequence data used to design subtype B vphu PCR primers. The PCR and 
sequencing primers are detailed in Table 2.1. 
 
2.2.2.2 PCR amplification of vphu  
 
A PCR protocol to amplify the ~300 bp sub B and C vphu was developed and 
optimised as recommended by the Vivid Colors™ pcDNA™6.2/C-emGFP-
GW/TOPO® Kit (Invitrogen). The gene fragments (246 bp, 249 bp and 261 bp for 
subtype B, 05ZAFV5, and 05ZAFV5 vphu respectively) were amplified using the 
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Expand High FidelityPLUS PCR System (Roche Applied Science GmbH, Mannheim, 
Germany), as per the manufacturer’s instructions. The PCR reaction mix is outlined in 
Table 2.2a. Reaction mixtures without template DNA (water blank) were set up as 
negative controls. The PCR reactions were carried out in a total volume of 50 μl, 
made up with sterile PCR-grade water.  
 
Thermal cycling conditions were optimised on the GeneAmp PCR Systems 2700 
thermocycler (Applied Biosystems, Foster City, CA), and were based on the 
suggested profile for the Expand High FidelityPLUS PCR System (Roche). Annealing 
temperatures and times were selected according to the relevant primer characteristics 
(Table 2.1). The PCR cycling parameters are outlined in Table 2.2b. 
 









hvpu B F CAGCCGCCATGGTGCCCATTATTG 63 24 58.3 
hvpu B R CAGGTCGTCAATGTCCC 52.8 17 58.8 
hFV5 F GAAGAGTGATGGTAGACTTG 58.4 20 45 
hFV5 R CAGATCGGCGGCGTCCAGC 68.8 19 74 





hFV15 R TAGATCATTCACGTCCAGG 58 19 47 
T7 
Promoter F 
TAATACGACTCACTATAGGG 56 20 40  
 
Sequencing FP2 R TCACCATGTTAACAGCATCAA 58 21 38 
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Table 2.2a: PCR Reaction mix 
 
Reagent Reaction Volume (µl) Final Concentration 
5X Buffer 10 1.5 mM (MgCl2) 
10mM dNTPs 1 200 µM 
Sense primer 2 0.4 µM 
Antisense primer 2 0.4 µM 
Template DNA 1 0.1 – 10 ng/µl 
Taq polymerase enzyme mix 
(5U/µl) 
0.5 2.5 U 
Distilled water 33.5 / 
TOTAL 50 / 
 
Table 2.2b: PCR thermal cycling conditions 
 
Phase Temperature (°C) Duration Cycles 
Initial denaturation 94 2 min 1 
Denaturation 94 20 s 
Annealing 51 30 s 
Elongation 72 30 s 
 
10 
Denaturation 94 20 s 
Annealing 51 30 s 
Elongation 72 30 s* 
 
25 
Final elongation 72 10 min 1 
Hold 4 infinite / 
* Plus 10 seconds on each elongation step. 
 
2.2.3 Visualisation of PCR amplicon 
 
PCR products were resolved on a 1.5 % Tris actetate ethylenediaminetetraacetic acid 
(EDTA) (TAE) agarose gel (Appendix C1), containing 0.5 µg/ml ethidium bromide 
(EtBr) solution (Promega Corporation, Madison, WI, USA), at 80 V for 1 hour. Results 
were visualized on a UV transilluminator and photographed using Quantity One 
V4.6.1 1D Analysis software (BioRad, Laboratories, CA, USA). All gels were run with 
the DNA Molecular Weight Marker X (Roche), which covers the fragment range from 
0.07 to 12.2 kb, for sizing purposes (Appendix D).  
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2.2.4 Purification of PCR products from TAE agarose gels 
 
The GFXTM PCR DNA and Gel Band Purification Kit (Amersham Biosciences, NJ, 
USA) was used to purify the PCR amplicon from an agarose gel. This was done 
because a discrete band was not previously obtained, and hence contamination by 
unrelated DNA sequences was observed. This kit uses a chaotropic agent to 
denature protein, dissolve agarose, and promote the binding of double-stranded DNA 
to a glass fibre matrix. Proteins and salt contaminants are washed away using an 
ethanolic buffer, and DNA is eluted in a low ionic strength buffer. Briefly, the PCR 
product was run on a fresh 1.5 % TAE agarose gel. The DNA band aligning with the 
correct size restriction fragment of the molecular weight marker was visualised by UV 
transillumination, and a ~300 mg gel band carefully sliced out of the gel using a sterile 
surgical blade. Three hundred microlitres capture buffer was added to the gel band in 
a 1.5 ml microcentrifuge tube (Eppendorf, Hamburg, Germany). The agarose was 
melted at 60 ° C for 15 min before transferring the sample to a GFX column, and 
incubating at room temperature for 1 min. The tube was centrifuged for 30 s at 15 000 
x g, and the flow-through discarded. The column was then washed with 500 µl Wash 
buffer at 15 000 x g for 30 s (Eppendorf centrifuge 5417). The DNA was incubated in 
50 µl elution buffer (Tris-EDTA, pH 8.0) for 1 min at room temperature, before 
centrifuging at 15 000 x g for 1 min to recover purified DNA. Purified DNA was used in 
all sub-cloning reactions.  
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2.2.5 TA cloning reactions 
 
The purified amplicons were used in TA cloning reactions in order to insert the vphu 
gene in frame with the emGFP gene into the pcDNA™6.2/C-emGFP-GW/TOPO® 
mammalian expression vector (Invitrogen). The cloning reaction was performed 
according to the manufacturer’s instructions. Briefly, two microlitres purified PCR 
product was mixed with 1 µl salt solution (200 mM NaCl, 10 mM MgCl2), 1 µl TOPO 
vector, and sterile water to a total reaction volume of 6 µl. The reaction was mixed 
gently and incubated at room temperature for 10 minutes. The reaction was then 
placed on ice before proceeding to the transformation step. A negative, PCR product-
free control was included in each experiment. 
 
2.2.6 Bacterial transformations and selection of recombinant clones 
 
The TA cloning reaction products were used to transform One Shot® TOP10 
chemically competent E. coli (Invitrogen), as per the manufacturer’s instructions. 
Briefly, two microlitres of the cloning reaction was added to a vial of competent E. coli 
(kept on ice) and mixed gently. The mixture was incubated on ice for 30 minutes, heat 
shocked in a 42 °C water bath for 60 s, and immediately transferred back to ice. Two 
hundred and fifty microlitres of room temperature Super Optimal (S.O.C.) broth 
medium (Invitrogen) was added before shaking the tube horizontally at 200 rpm in a 
37 °C incubator for one hour. Aliquots of the bacterial cell mix from each 
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transformation (50 µl and 200 µl), including the negative control, were spread on pre-
warmed selective LB plates, containing 100 µg/ml ampicillin (Roche) (Appendix C1), 
and incubated overnight at 37 °C. 
 
The next day, ten discrete colonies from each transformation were selected and used 
to inoculate 5 ml aliquots of LB containing 100 µg/ml ampicillin (Roche) (Appendix 
C1), and cultured overnight at 37 °C in a shaking incubator at 225 rpm. Overnight 
cultures were used to make glycerol stocks and for plasmid MiniPrep DNA-isolations 
(see section 2.2.7). Briefly, 0.85 ml bacterial cell culture containing the required clone 
was mixed with 0.15 ml filter-sterilised glycerol (Saarchem, Merck Chemicals, 
Modderfontein, SA). This mix was transferred to a 1.8 ml cryovial (Nalge Nunc Int., 
Rochester, NY, USA), and frozen overnight in a “nest” box at -80 °C, before 
transferring to liquid nitrogen storage. 
 
2.2.7 Recombinant plasmid DNA isolation 
 
Recombinant plasmid DNA was isolated using the GenElute™ HP Plasmid MiniPrep 
and MaxiPrep Kits (Sigma-Aldrich Inc., St Louis, USA). The binding columns in these 
kits were used in the spin purification format. For the MiniPrep kit, the overnight 
recombinant E. coli culture was harvested by centrifugation at 12 000 x g for 1 min 
(Eppendorf centrifuge 5415D) and subjected to the modified alkaline-SDS lysis 
procedure, as per the manufacturer’s instructions. Briefly, the cell pellet was 
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resuspended in 200 µl Resuspension Buffer and lightly vortexed before addition of 
200 µl Lysis Buffer and gentle inversion. The mixture was allowed to clear before 
adding 350 µl Neutralisation Solution and inverting six times. The cell debris was 
pelleted at 12 000 x g for 10 min, during which time 500 µl Column Prep Solution was 
added to the binding column, centrifuged at the maximum speed and the flow-through 
discarded. The lysate was cleared with a filter syringe by centrifuging for 1 min, 
leaving the DNA bound to the silica-based column membrane. The remaining 
contaminants were removed by a wash step where 750 µl Wash Solution was added, 
centrifuged for 1 min, and the flow-through discarded. Finally, the bound DNA was 
eluted in 60 µl Elution Solution at 12 000 x g for 1 min and stored at -20 °C. The 
clones containing the genes of interest were cultured overnight on a large scale (250 
ml ampicillin-containing LB), the plasmid DNA purified by the GenElute™ HP Plasmid 
MaxiPrep Kit (Sigma-Aldrich) and stored at -20 °C for use in transfection reactions. 
The GenElute™ HP Plasmid MaxiPrep Kit (Sigma-Aldrich) was also used for the 
large-scale preparation of the subcellular marker plasmids, pDsRed-ER, pDsRed-
Golgi, and pDsRed-Mem (Clontech). Plasmid DNA concentration was determined by 





2.2.8 Characterisation of recombinant clones by restriction enzyme digest and 
agarose gel electrophoresis 
 
To confirm the presence of the insert in pcDNA™6.2/C-emGFP, a restriction enzyme 
digest was performed on the selected clones. An EcoRI digest of pcDNA™6.2/C-
emGFP-Vphu results in two bands: the excised vphu fragment of ~300 bp, and the 
original 5.9 kb plasmid. The digestion reaction for each clone contained (in order): 
11.5 µl sterile water, 2 µl 10X buffer, 5 µl plasmid DNA, and lastly 1.5 µl EcoRI 
enzyme (New England BioLabs Inc., Ipswich, MA, USA). The reaction was mixed 
gently and incubated in a 37 °C water bath for one hour. The entire twenty microlitre 
reaction was run on a 0.8%, EtBr-treated, TAE agarose gel at 80 V for one hour.  
 
2.2.9 Characterisation of recombinant clones by cycle sequencing reactions 
 
Recombinant Vpu-emGFP plasmids, as defined by restriction enzyme digests, were 
sequenced to verify the orientation of the insert, and to ensure the insert was in frame 






2.2.9.1 Sample preparation 
 
The T7 promoter sequence forward primer and the FP2 reverse primer (Table 2.1) 
were used to sequence the purified plasmid DNA in both directions using the Big Dye 
Terminator V3.1 Cycle Sequencing kit (Applied Biosystems), as per the 
manufacturer’s instructions. Briefly, a cycle sequencing reaction mixture consisting of 
4 μl 2.5X Terminator Ready Reaction Mix, 4 μl 5X Sequencing Buffer, 2 μl purified 
DNA template, and 9 μl reagent-grade water, was added to 1.1 μl of each individual 
primer (3.2 ρmol working concentration) making up a volume of 20.1 μl.  
 
2.2.9.2 Thermal cycle sequencing 
 
Thermal cycle sequencing reactions were performed in the GeneAmp PCR Systems 
2700 thermal cycler (Applied Biosystems). Thermal cycle sequencing conditions were 
set as recommended for the Big Dye Terminator V3.1 Cycle Sequencing system: a 
rapid thermal ramp to 96 °C for 1 min, 25 cycles of denaturation for 10 s at 96 °C, 
annealing for 5 s at 50 °C, and elongation for 4 min at 60 °C, concluding in a rapid 




2.2.9.3 Purification of extension products 
 
Cycle sequencing products were purified of unincorporated dye terminators, salts, 
dNTPs, and ddNTPs by isopropanol precipitation, prior to being run on the ABI Prism 
3100 Genetic Analyzer (Applied Biosystems). This step was done to avoid excess 
dye terminators obscuring data in the initial part of the sequence, thereby interfering 
with base calling. Isopropanol precipitation was adapted from the ViroSeq HIV-1 
Genotyping System (Celera Diagnostics, Alameda, CA, USA). Completed twenty 
microlitre cycle sequencing reactions were transferred to a MicroAmp 96-well Optical 
Reaction Plate (Applied Biosystems). Eighty microlitres of 80% isopropanol was 
added to each well, mixed by reverse pipetting, sealed with a plate cover, and 
incubated in the dark at room temperature for 15 min. The plate was then centrifuged 
for 45 min at 2000 x g (Eppendorf centrifuge 5810). The plate was immediately 
uncovered and inverted onto paper towel, and spun in this inverted position for 1 min 
at 700 x g. The plate was allowed to air dry, protected from light, in an upright position 
for 3 min, before resuspending the purified DNA pellet in 20 μl HiDi Formamide 
(Applied Biosystems). Resuspended purified DNA was either stored at -20 °C, or 





2.2.9.4 Sample electrophoresis  
 
Purified cycle sequencing products were run on the ABI Prism 3100 Genetic Analyzer 
(Applied Biosystems). This automated sixteen-capillary sequencer separates 
fragments according to size on a 6% acrylamide gel. Electrophoresis was configured 
to a 50 cm capillary running POP-6 polymer gel (Applied Biosystems) on a standard 
run module. For data analysis, dye set/primer (mobility) files were set as 
recommended by the manufacturer. The Big Dye Terminator V3.1 Matrix Standard 
(Applied Biosystems) was used for spectral calibration of dye set Z. 
 
2.2.9.5 Sequence data analysis 
 
Sequence gel analysis and data extraction was performed using the 3100 Genetic 
Analyzer software suite, specifically the Data Collection V1.0 and Sequencing 
Analysis V3.3 programs (Applied Biosystems). The resulting overlapping sequence 
fragments for each isolate were edited and automatically assembled into a single 
contig by the Sequencher V4.5 program (Genecodes, Ann Arbor, MI). Assembly 
parameters were set to allow for a minimum homology match of 85%, and a minimum 
overlap of 20 nucleotides, using the Dirty Data algorithm.  
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2.3 Transfections of mammalian cell lines 
 
2.3.1 HEK 293T mammalian cell line 
 
Human Embryonic Kidney (HEK) 293T cells were used in all transfection and 
confocal microscopy experiments. The cells were seeded in 75 cm3 flasks (Nalge 
Nunc Int.) and maintained in complete Dulbecco’s Modified Eagle’s Medium (DMEM) 
(Appendix C2). Cells were passaged as described in section 2.3.2 below.  
 
2.3.1.1 Cell culture conditions and passage 
 
HEK 293T cells were incubated at 37 °C in a 5% CO2 atmosphere. Cells were 
passaged every four to six days when subconfluent, using trypsin EDTA solution 
(Sigma-Aldrich). Briefly, old media was discarded and the cell monolayer washed 
gently with 1X Phosphate Buffered Saline (PBS) (Sigma-Aldrich). Cells were 
dislodged by adding 1 ml trypsin EDTA solution, pouring off the excess, and 
incubating for ~3 minutes at 37 °C. Cells were then tapped off the flask surface and 
resuspended to a concentration of 4 X 106 cells in 20 ml complete DMEM in a 75 cm3 
flask (Nalge Nunc Int.). Cell concentration was determined by staining cells with 0.4% 
Trypan Blue solution (Sigma-Aldrich), and assessing the viable cell count on an 
Improved Neubauer haemocytometer (Merck, Darmstadt, Germany). Briefly, ten 
microlitres cell suspension was added to 90 µl 0.4% Trypan Blue solution and mixed 
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thoroughly before pipetting onto a clean haemocytometer and allowing diffusion. 
Viable cells do not take up the dye and appear white under a light microscope. Live 
cells were counted in all four primary squares and averaged for one square to denote 
the number of cells in 1 X 10-4 ml. By taking into account the dilution factor of ten, the 
cell count was calculated per ml of cell suspension and adjusted accordingly. 
 
2.3.1.2 Storage of mammalian cell strains 
HEK 293T cells were frozen in a 90% fetal calf serum (FCS), 10% dimethyl sulfoxide 
(DMSO) freezing mix, and stored in liquid nitrogen. Cell stocks were prepared as 
follows: 1 ml aliquots of cell suspension were centrifuged in 1.8 ml cryovial (Nalge 
Nunc Int.) at 320 x g for 2 min (Eppendorf centrifuge 5810). The supernatant was 
carefully pipetted off the cell pellet and the pellet resuspended in 1 ml of the 
appropriate freezing mix. Cryovials were transferred immediately to a nest box at -80 
°C and stored overnight before transferring to liquid nitrogen for indefinite storage.  
 
2.3.2 Vphu-emGFP transfections of HEK 293T cells 
 
2.3.2.1 Confirmation of Vphu expression by fluorescence microscopy 
 
The subtype B and C pcDNA™6.2/C-emGFP-Vphu vectors were transfected singly 
into HEK 293T cells and the expression of the fusion protein confirmed by fluorescent 
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microscopy. Cells were seeded the day before transfections at 1.2 x 106 cells in 25 
cm3 culture flasks (Nalge Nunc Int.) containing 6 ml complete DMEM. Transient 
transfections were performed using Polyfect reagent (Qiagen Inc., Valencia, CA, 
USA). Briefly, the transfection mix containing 4 µg plasmid DNA in 150 µl DMEM 
without supplements and 40 µl Polyfect, was incubated for 10 min at room 
temperature to allow complex formation. One millilitre of complete DMEM was added 
to the transfection mix before the entire mix was added to cells with fresh complete 
DMEM. Cells were incubated at 37 °C in a 5% CO2 atmosphere, and prepared for 
fluorescent microscopy at 24 hours post-transfection. Fluorescence was detected 
using a Zeiss Carv Axiovert 100M inverted confocal microscope (Carl Zeiss, 
Oberkochen, Germany) equipped with a mercury-arc lamp and a closed circuit 
detection (CCD) camera. The emGFP was excited at 487 nm, the emitted light 
collected at 509 nm (Tsien, 1998), and detected with a standard fluorescein iso-
thiocyanate (FITC) filter set. The pcDNA™6.2/C-emGFP-CAT vector was also 
transfected as above into HEK 293T cells to act as a positive control for emGFP 
expression. 
 
2.3.2.2 Confirmation of Vpu expression by SDS-PAGE and Western blot 
analysis 
 
Expression of recombinant proteins was confirmed by sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE) and Western blot analysis of 
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transfected cell lysates. HEK 293T cells were transfected with 4 µg pcDNA™6.2/C-
emGFP-Vphu as described above, and assayed at 24 hours and 48 hours post-
transfection. Mock transfected (empty vector) and untransfected cells were also 
assayed at these time points. Approximately 1.2 x 106 cells were washed and scraped 
into 1 ml 1X PBS (Sigma-Aldrich), before harvesting at 15 000 x g for 5 min 
(Eppendorf centrifuge 5810). Cells were resuspended in 50 µl cell lysis buffer and 
vortexed thoroughly. The cell lysate was centrifuged at 10 000 x g for 10 min at 4 °C, 
the supernatant transferred to a fresh tube and stored at -80 °C until assayed for 
protein concentration. Twenty micrograms of cell lysate was resolved on a 12.5% 
SDS-PAGE gel (see Appendix C3 for details of the following solutions and buffers). 
Briefly, a 4.5% stacking gel and 12.5% resolving gel were prepared in duplicate, set, 
and assembled into PAGE apparatus (BioRad) with electrophoresis buffer. Fifteen 
microlitres each of the sample and the 2X loading dye were added to a 1.5 ml 
microcentrifuge tube (Eppendorf) and boiled for 5 min before transferring to ice. The 
mix was loaded onto the gel alongside 10 µl Prestained 6-175 kDa Protein Marker 
(New England BioLabs) (Appendix D). The gel was run at 10 mA per gel for stacking, 
and then at 25 mA per gel until the dye front was seen a half centimetre from the 
bottom of the gel (~2.5 hours).  
 
After electrophoresis, one gel was stained with Coomassie Blue dye to visualise all 
protein and the other was used for immunoblotting as described below. Coomassie 
staining was carried out by covering the gel in 500 ml of the dye and shaking gently at 
 54
room temperature for three to four hours. The stain was then poured off and the gel 
submerged in 250 ml destain solution. The destain solution was changed three times 
and the destaining continued until background staining had been removed. The 
Coomassie gel was visualised on a white light box and the bands compared to the 
subsequent Western blot image. Gel images were captured using Quantity One 
V4.6.1 1D Analysis software (BioRad).  
 
The remaining gel was used for transfer of proteins to Hybond-C Extra Nitrocellulose 
Membrane (Amersham) using a Trans-Blot® SD Semi Dry Transfer Cell (BioRad), as 
per manufacturer’s instructions. Briefly, the gel was equilibrated in transfer buffer for 
an hour, and then transferred onto pre-equilibrated Hybond C membrane at a 
constant current of 60 mA for 35 min. The membrane was then blocked for an hour in 
100 ml 5% fat free milk powder dissolved in T-TBS to prevent non-specific antibody 
binding. The membrane was then rinsed three times with T-TBS, prior to primary 
antibody binding. The membrane was incubated for one hour with 2 ml of the 
recommended 1:5000 dilution of the primary antibody HIV-1NL4-3 Vpu Antiserum, 
(AIDS Research and Reference Reagent Program, NIH, Bethesda) before washing 
three times for 5 min in T-TBS. The membrane was then incubated for one hour in 2 
ml of a 1:2000 or a 1:4000 dilution of the Horseradish Peroxidase (HRP) conjugated 
goat anti-rabbit IgG secondary antibody (Zymed Laboratories, San Francisco, CA, 
USA), and washed three times as before to remove any unbound HRP-conjugate. 
Enhanced chemiluminescence (ECL) detection of the protein was performed using 
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the Pierce SuperSignal West Pico Chemiluminescent Substrate (Thermo Fisher 
Scientific). Briefly, working solutions of the substrates (SuperSignal West Pico Stable 
Peroxide Solution and Luminol Enhancer Solution) were prepared according to the 
manufacturers’ instructions. Equal volumes of the detection solutions (1 ml each) 
were mixed and added to the membrane for 1 min. The blot was then covered with 
clear plastic wrap and placed protein side up on a Kodak X-Omatic cassette 
(Eastman Kodak Company, Rochester, NY, USA). Fuji Super Rx Medical X-Ray film 
(Africa X-Ray, Industrial and Medical, La Rochelle, SA) was placed carefully over the 
covered blot and exposed for 1 min. Standard autoradiographic techniques allowed 
visualisation of the fusion protein using developing solution and fixative.  
 
2.3.3 Cotransfections of HEK 293T cells with Vphu-emGFP and subcellular 
localisation plasmids 
 
2.3.3.1 Optimisation of cotransfections 
 
The subtype B and C pcDNA™6.2/C-emGFP-Vphu recombinant plasmids were 
cotransfected with pDsRed-ER, pDsRed-Mem, or pDsRed-Golgi into HEK 293T cells 
to confirm the presence of Vpu at different subcellular compartments. The plasmid 
DNA concentration of all clones was measured by spectroscopy at 260nm and 280nm 
on a Nanodrop 1000 (Thermo Fisher Scientific) prior to transfection reactions. 
Transfection reactions were optimised with respect to cell number at seeding, ratio of 
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Vphu-emGFP to DsRed plasmids, ratio of plasmid DNA concentration to transfection 
reagent volume, transfection reagent type, and slide type.  
 
The amount of cells seeded was optimised so that they could withstand any toxic 
effects of the transfection reagent, while avoiding becoming excessively confluent by 
the 60 hours post-transfection time point. The numbers of cells seeded varied from 5 
x 106 cells in 25 cm3 flasks, to 250 000 cells in 2 ml chamber slides. The ratio of 
pcDNA™6.2/C-emGFP-Vphu to pDsRed was optimised to ensure cells expressed 
both markers. The ratio was also important in ensuring the brightest signal and the 
least noise are observed under the confocal microscope. A total of 4 µg plasmid DNA 
was used and split between the dsRed and Vphu-emGFP plasmids 1:1, 1:2, and 1:3 
respectively. The efficiency and cytotoxicity of Polyfect (Qiagen) and Lipofectamine 
2000 (Invitrogen) transfection reagents were compared. Reagent mixes were made 
up according to the manufacturer’s instructions, and were used as a starting point for 
optimisation. The ratio of plasmid DNA concentration to transfection reagent volume 
was then varied 1:1, 1:2, 1:5.  
 
The best possible method to view the transfected HEK 293T cells under the confocal 
microscope was determined by seeding the cells in various formats. Cells were 
transfected in 25 cm3 flasks, six-well plates, and 5 ml or 2 ml Lab-TeK II Chamber 
Slides (Nalge Nunc Int.). Cells were then transferred onto glass slides after 
transfection and then fixed, or fixed in the chamber slides. Cells were also viewed 
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live, by pipetting 100 µl cell suspension directly onto a glass slide. Transfection 
efficiency and cell cytotoxicity was evaluated visually by fluorescence microscopy as 
described above in section 2.3.2.1. The optimal cotransfection protocol was employed 
for all the subsequent cotransfection experiments, and is described below in section 
2.3.3.2. 
 
2.3.3.2 Cotransfection experiments 
 
Transient transfections were performed using Lipofectamine 2000 (Invitrogen), 
according to the manufacturer’s instructions. Briefly, cells were seeded onto Lab-TeK 
II Chamber Slides (Nalge Nunc Int.) 24 hours prior to transfection at 65% confluency 
(~600 000 cells), in media without antibiotics. Two micrograms each of the Vpu-
emGFP (05ZAFV5, 05ZAFV15 or subtype B) and DsRed plasmids (ER, Golgi, or 
Membrane) was diluted in 200 µl Opti-MEM (Invitrogen) while 4 µl Lipofectamine 
2000 was diluted in 200 µl Opti-MEM. Samples were incubated for 5 min at room 
temperature before combining and briefly vortexing. The mixture was then incubated 
for 20 min at room temperature to allow complex formation. The reaction mix was 
added to the cells and made up to 3 ml with DMEM without of antibiotics. Cells were 
processed for confocal microscopy 24, 48, and 60 hours post-transfection. For cells 
assayed at 48 and 60 hours, the media was replaced with fresh complete DMEM 24 
hours post-transfection. Cells were incubated at 37 °C in a 5% CO2 atmosphere. 
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2.4 Confocal fluorescence microscopy analysis 
 
2.4.1  Optimisation of cell fixation conditions and confocal microscope settings  
 
Cell fixation conditions were optimised with respect to fixation reagent and incubation 
time. HEK 293T cells were fixed under three different conditions and the results 
compared. Firstly, 100 µl pre-cooled 3% formaldehyde in PBS was added to the 
washed cell monolayer and incubated for 15 min at room temperature. Secondly, 100 
µl ice cold 100% methanol was added to cells and incubated for 10 min at -20 °C. 
Finally, 100 µl 3% paraformaldehyde and 0.02% glutaraldehyde in PBS was added to 
cells and incubated for 15 min at room temperature. Cells were washed three times 
with 1X PBS (Sigma-Aldrich) after each incubation, and processed for microscopy as 
described below. Cell viability was then visually determined by microscopy. 
 
Confocal microscopy settings were optimised with respect to magnification and 
spectral overlap in multichannel mode. The confocal microscope settings were 
adjusted to reduce cross emission. This was achieved by adjusting the laser intensity, 
as well as the gain and offset levels of the photo multiplier tube (PMT). The spinning 
disk was utilised to increase the sharpness of the image. Optimal cell processing and 




2.4.2 Cell preparation for confocal microscopy 
 
Transfected and untransfected negative control HEK 293T cells were processed for 
confocal microscopy at 24, 48, and 60 hours post-transfection. Growth media was 
removed and the cells were washed briefly with 1X PBS (Sigma-Aldrich) at room 
temperature. Cells were fixed onto the chamber slides using 200 µl freshly prepared 
3% formaldehyde solution, for 15 minutes at room temperature. The fixative was 
removed and the cells gently rinsed with 1X PBS. The nuclei were stained using 200 
µl 100ng/ml DAPI solution (Sigma-Aldrich) in the dark for 15 minutes (Appendix C4). 
The chamber was removed and coverslips were then mounted onto the slides using 
80 µl Fluorsave Reagent (Calbiochem, Darmstadt, Germany) and allowed to set in 
the dark at room temperature for 60 min.  
 
2.4.3 Detection of Vphu-emGFP fusion proteins and subcellular marker 
proteins by confocal microscopy 
 
Cells were viewed at each time point using a Zeiss Carv Axiovert 100M inverted 
confocal microscope (Carl Zeiss, Oberkochen, Germany). The emGFP was excited at 
487 nm, and the emitted light collected at 509 nm (Tsien, 1998) and detected with a 
standard FITC filter set, while the DsRed-Monomer was excited 557nm and the 
emitted light collected at 585 nm and detected with a standard tetramethyl rhodamine 
iso-thoicyanate/Phycoerythrin (TRITC/PE) filter set. Fluorescent digital images of cells 
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identified expressing both fluorescent proteins were collected separately and 
superimposed in multi-track channel mode (sequential excitation/emission) using the 
Plan-Neofluar 630x objective or 100x /1.30 Oil objective. Images were processed and 
analysed using Axiovision 2.0 software (Carl Zeiss). All images were collected under 
the same photomultiplier detector conditions and pinhole diameter. Untransfected 
cells and cells transfected with an empty vector were used as negative controls and 
processed for fluorescent microscopy as described above. Differential interference 
contrast images were collected simultaneously with fluorescence images using the 
transmitted light detector. Transfection experiments were repeated five or more times 








3.1       Viral isolate selection and codon optimisation 
 
Comparison of the previously sequenced HIV-1 subtype C isolates allowed for the 
selection of the two isolates 05ZAFV5 and 05ZAFV15 used in this study (Bell, Connell 
et al. 2007). The sequence data distinguished 05ZAFV5 as having a six amino acid 
insert at the N-terminus and a predicted protein length of 86 amino acids. In contrast, 
05ZAFV15 has a two amino acid insert at the N-terminus and is 82 amino acids in 
length. 05ZAFV5 was therefore selected as a representative subtype C isolate, and 
05ZAFV15 was selected because it more closely resembles the 81 amino acid 
subtype B Vpu in length. The vpu genes from these two isolates were codon-
optimised for optimal expression in mammalian cells. The subtype B vphu is the 
codon-optimised form of the wild-type vpu from the subtype B strain, NL4-3. The 
predicted amino acid sequences for the native and codon-optimised recombinant 
clones of subtype B Vphu (pcDNA-Vphu), subtype C 05ZAFV5 (FV5_pCR Script), 
and 05ZAFV15 (FV15_pCR Script) Vphu are depicted in Figure 3.1. Critical sequence 
motifs are highlighted in colour.  
 
3.2 PCR optimisation and amplification of vphu 
 
PCR primers were designed so that the ~300 bp subtype B and C vphu genes could 
be amplified and directionally cloned into the pcDNA™6.2/C-emGFP-GW/TOPO® 
vector, in frame with the C-terminal emGFP tag. The subtype B and C vphu genes
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                        *        20         *        40         *        60         *        80
B.NL4_3      : MQ------PIIVAIVALVVAIIIAIVVWSIVIIEYRKILRQRKIDRLIDRLIERAEDSGNESEGEVSALVEMGVEMGHHAPWDIDDL : 81 
B.pcDNA(h)   : .V------............................................................................... : 81 
C.05ZAFV5    : .VDLLARVDYRLGVG..L..L....I..T.AY.....LV...R.....R.IR............DTEE.STL-.D..PLRLL.AA.. : 86 
C.05ZAFV5(h) : .VDLLARVDYRLGVG..L..L....I..T.AY.....LV...R.....R.IR............DTEE.STL-.D..PLRLL.AA.. : 86 
C.05ZAFV15   : .VTL----DYNIT.A.F...L....I..T.AY.....LRK........E.IR............DTEE.AT.-.D..QLRLL.VN.. : 82 
C.05ZAFV15(h): .VTL----DYNIT.A.F...L....I..T.AY.....LRK........E.IR............DTEE.AT.-.D..QLRLL.VN.. : 82 
 
                N-terminal   Transmembrane                 α-helix 1                 α-helix 2 




V14-S31  Hydrophobic transmembrane domain 
W30   Tryptophan involved in channel gating 
E36-L41  Hinge Region containing salt bridge 
S60-S64  CK-II phosphorylation site containing critical serines 
T73-D77  Putative CK-II site in subtype C Vpu 
L81-L84  Unique dileucine motif in subtype C Vpu 
 
Figure 3.1: An alignment of the deduced amino acid sequences of the wild type and codon-optimised forms of the subtype B NL4-3 Vpu, and 
the subtype C 05ZAFV5 and 05ZAFV15 Vpu proteins. The sequences are compared to wild type subtype B NL4-3 Vpu (top), and the 
humanised form is indicated by (h). Dots represent identical residues, and variant residues are shown. The N-terminal domain, 
transmembrane domain, and cytoplasmic helices are indicated. The critical phosphoserine residues are shown in red lettering. The glycine 
insertions in the subtype B proteins are also shown in red lettering. Known functional domains and critical residues are highlighted and are 
annotated in the accompanying key. 
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were successfully PCR amplified from the pcDNA-Vphu, FV5_pCR Script, and 
FV15_pCR Script recombinant vectors, respectively, producing an approximately 300 
base pair amplicon as seen on a 1.5% agarose gel (Figure 3.2A). 
 
3.3 Construction of Vphu-emGFP fusion proteins 
 
Overall, the subtype B and C vphu genes were successfully TA cloned into the 
pcDNA™6.2/C-emGFP expression vector, and used to transform competent E. coli 
TOP 10 cells. Plasmid DNA from positive clones was purified and characterised by 
restriction enzyme digestion and sequencing. The pDsRed-Monomer-Golgi, 
pDsRed2-ER, and pDsRed-Monomer-Mem vectors were successfully transformed 
into competent E. coli TOP 10 cells and the purified plasmid DNA employed in 
cotransfection experiments.   
 
3.3.1 Characterisation of recombinant clones by restriction enzyme digest and 
agarose gel electrophoresis 
 
The correct clones were identified by an EcoRI restriction enzyme digest. The 
pcDNA3.1-Vphu was digested by EcoRI at position 953 and linearised, identified by a 
single band at approximately 5.7 kb when resolved on a 0.8% agarose gel (Figure 
3.2B, lane 4). The pcDNA™6.2/C-emGFP-Vphu, however, was digested at positions 
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Figure 3.2: Construction of the Vphu-emGFP fusion proteins. (A) Representative image of vphu 
PCR amplicon. Amplicons were resolved by 1.5% agarose gel electrophoresis, at 85 V for 45 min. 
Lane 1: 05ZAFV5 vphu. Lane 2: 05ZAFV15 vphu. Lane 3: Subtype B vphu. Lane 4: negative control. 
(B) Confirmation of vphu inserts by restriction digest and agarose gel electrophoresis. PcDNA3.1-
Vphu and pcDNA™6.2/C-emGFP-Vphu were digested at 37°C for one hour with the restriction 
enzyme, EcoRI. Digests were resolved by 0.8% agarose gel electrophoresis, at 85 V for 1 hour. 
Lane 1: FV5 pVphu-emGFP. Lane 2: FV15 pVphu-emGFP. Lane 3: SubB pVphu-emGFP. Lane 4: 
pcDNA3.1-Vphu. (C) Representative image of the plasmids used in this study. Purified plasmid 
DNA as resolved by 0.8% agarose gel electrophoresis, at 85 V for 1 hour. Lane 1: FV5 pVphu-
emGFP. Lane 2: FV15 pVphu-emGFP. Lane 3: Sub B pVphu-emGFP. Lane 4: pDsRed-ER. Lane 5: 
pDsRed-Goli. Lane 6: pDsRed-Mem. Lane 7: pcDNA6.2-emGFP (empty vector). Lane 8: pCAT-
emGFP (positive control). All gel bands were sized in base pairs against Molecular Weight Marker 
X (MWM) (Appendix D) and viewed by UV transillumination.  
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 882 and 900 into two fragments of approximately 5.9 kb and 0.3 kb in size (Figure 
3.2B, lanes 1, 2, and 3). 
 
3.3.2 Characterisation of recombinant clones by cycle sequencing reactions 
 
The purified plasmid DNA for the pcDNA6.2/C-emGFP-Vphu was sequenced using a 
T7 promoter forward primer and a FP2 reverse primer before extensive analysis. True 
expression clones were verified as having the vphu insert, in the correct orientation, 
with no stop codon, and in frame with the emGFP gene. One clone each for subtype 
B, and the subtype C 05ZAFV5 and 05ZAFV15 isolates was selected for further 
studies. Plasmids were resolved on a 0.8% agarose gel and their sizes confirmed, 
with the subtype B and C pcDNA6.2/C-emGFP-Vphu sitting at approximately 6.1 kb, 
pDsRed-ER at 4.7kb, pDsRed-Golgi at 4.9 kb, and pDsRed-Mem at 5.3 kb (Figure 
3.2C). The positive control plasmid, pcDNA6.2/N-emGFP/GW/CAT (6.5 kb) and the 








3.4 Transfections of mammalian cell lines 
 
3.4.1 Confirmation of Vphu expression by fluorescence microscopy and 
western blot analysis 
 
Transfection efficiencies of each expression clone (namely, subtype B pVphu-
emGFP, subtype C 05ZAFV5 and 05ZAFV15 pVphu-emGFP, pDsRed-
ER/Golgi/Mem) were carried out in HEK 293T cells using Polyfect reagent (Qiagen). 
The empty vector, pcDNA6.2/C-emGFP was used as a negative control by mock 
transfection to evaluate the results. Optimum transfection conditions were obtained 
when overnight cultures of 1.2 x 106 cells in a 25 cm3 culture flask were incubated 
with a transfection mix of 4 µg plasmid DNA in 150 µl unsupplemented DMEM, and 
40 µl Polyfect. Optimised transfection reactions resulted in the successful expression 
of functional fusion proteins and subcellular localisation proteins in HEK 293T cells. 
Functional proteins were observed by fluorescence in the cells 24 hours post-
transfection, under a Zeiss Carv Axiovert 100M inverted confocal microscope using 
the 100X oil immersed objective. Single transfections of HEK 293T cells by FV5 
Vphu-emGFP (Figure 3.3A), FV15 Vphu-emGFP (Figure 3.3B), or subtype B Vphu-
emGFP (Figure 3.3C) resulted in nodes of bright green fluorescence 24 hours post 
transfection in the perinuclear region. The positive control, pcDNA6.2/C-
emGFP/GW/CAT, also showed bright green fluorescence at 24 hours post-
transfection (Figure 3.3D), but the expression is seen as a more diffuse pattern 
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throughout the cell. Transfection with the empty vector, pcDNA6.2/C-emGFP results 
in no fluorescence (Figure 3.3E). Cell integrity remained intact following transfection 
and fixing as seen with a transmitted light phase image (Figure 3.3F). Expression of 
the DsRed vectors was also confirmed by single transfection reactions in HEK 293T 
cells. The plasmids were observed to successfully localise to the ER (Figure 3.4A), 
the Golgi apparatus (Figure 3.4B), and cellular membranes (Figure 3.4C) as observed 
by confocal microscopy 24 hours post-transfection.  
 
Expression was also demonstrated by glycine-containing SDS-PAGE and Western 
blotting of HEK 293T cell lysates 24 hours and 48 hours post-transfection with 
subtype B and C pcDNA™6.2/C-emGFP-Vphu (Figure 3.5, Lanes 1, 2, and 3). Mock 
transfected (empty vector) and untransfected cells were also assayed (Figure 3.5, 
Lanes 4). Vpu has an apparent molecular mass of 16 kDa in glycine-containing SDS-
PAGE gels, or 9 kDa in Tricine containing SDS-PAGE gels (Schubert, Henklein et al. 
1994). Blotting with HIV-1NL4-3 Vpu rabbit antiserum and subsequent visualisation by 
ECL resulted in a positive signal from a band at 43 kDa representing the 16 kDa Vphu 
protein fused to the 27 kDa emGFP protein (Figure 3.5B). Significant background was 
noted using the Vpu rabbit antiserum at the recommended dilution, and the HRP-
conjugated goat anti-rabbit IgG secondary antibody at dilutions of 1:2000 and 1:4000. 
This is commonly observed when blotting with polyclonal antiserum. The expression 






Figure 3.3: Expression of functional Vphu-emGFP subtype B (A) subtype C 05ZAFV5 (B)  or 
05ZAFV15 pcDNA™6.2/C-emGFP-Vphu (C), positive control plasmid, pcDNA™6.2/C-
emGFP/CAT, (D), negative control empty pcDNA™6.2/C-emGFP plasmid (E), and untransfected 
cells (F), at 24 hours post-transfection of HEK293T cells, as viewed by confocal microscopy. 
Expressed protein is seen as green. Nuclei are stained blue in (F). Representative fluorescent 
digital images were collected using the Plan-Neofluor 100x /1.30 Oil objective and analysed 
using Axiovision 2.0 software. Panel E and F show the transmitted light phase image merged 




Figure 3.4: Expression of functional DsRed subcellular localisation proteins. HEK 293T cells 
were transfected with vectors expressing a subcellular localisation protein fused to the 
fluorescent protein, DsRed. At 24 hours post-transfection, cells expressing DsRed were 
identified and fluorescence micrographs were collected using a confocal microscope. Images 
represent cells transfected with either pDsRed-ER (A) pDsRed-Golgi (B) or pDsRed-Mem (C). 
Expressed DsRed proteins are seen as red. Nuclei are stained blue. Representative fluorescent 
digital images of DsRed expression were collected using the Plan-Neofluor 100x /1.30 Oil 
objective and analysed using Axiovision 2.0 software. 
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the subtype C fusion-proteins (Figure 3.5B, Lanes 1 and 2) at 24 hours and 48 hours 
post-transfection. Expression also remains relatively stable from 24 hours to 48 hours 
showing no significant increase or decrease. No protein was detected when cells 
were transfected with an empty vector (Figure 3.5B, Lanes 4).  
 
3.4.2 Optimisation of cotransfection experiments 
 
The subtype B or C pcDNA™6.2/C-emGFP-Vphu recombinant plasmids were 
cotransfected with pDsRed-ER, pDsRed-Golgi, or pDsRed-Mem into HEK 293T cells 
to confirm the presence of Vpu at different subcellular compartments. Cotransfection 
reactions were optimised with respect to cell number at seeding, ratio of pVphu-
emGFP to pDsRed, ratio of plasmid DNA concentration to transfection reagent 
volume, transfection reagent, and slide type. Transfection efficiency and cell 
cytotoxicity was evaluated visually by fluorescence and light microscopy respectively, 
as described in section 3.4.1 (Figure 3.6). Lipofectamine 2000 was the preferred 
reagent as it caused less cytotoxicity than Polyfect when applied to the cells alone. 
The amount of cells seeded varied from 5 x 106 cells in 25 cm3 flasks, to 250 000 cells 
in 2ml chamber slides (Table 3.1). Cells seeded at greater than 60% confluency 
resulted in excessive confluence by 60 hours post-transfection, with the majority of 
the cells detached and floating in the media. In contrast, the transfection mix had a 
detrimental effect on cells seeded at less than 60% confluency. Cells seeded onto 2 
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ml Lab-TeK II Chamber Slides (Nalge Nunc Int.) demonstrated the best adherence. 
The ratio of pcDNA™6.2/C-emGFP-Vphu to pDsRed was optimised to ensure a large 
percentage of cells expressed both markers. The ratio was also important in ensuring 
that the brightest signal and the least noise were observed under the confocal 
microscope. A total of 4 µg plasmid DNA was used and split between the dsRed and 
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24 hr 48 hr
Figure 3.5: SDS-PAGE (A) and Western blot analysis (B) of HEK 293T cell lysates 
transfected with subtype B, or subtype C pcDNA™6.2/C-emGFP-Vphu, or an empty vector 
for 24 and 48 hours. Recombinant protein expression (approximately 43 kDa) was detected 
using HIV-1 NL4-3 Vpu rabbit antiserum. The protein marker in kDa is indicated on the left 
(Appendix D). Lane 1: FV5 pVphu-emGFP. Lane 2: FV15 pVphu-emGFP. Lane 3: Sub B 
pVphu-emGFP. Lane 4: Mock transfected. 
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3.5 Confocal microscopy analysis to determine subcellular localisation 
 
3.5.1 Optimisation of confocal microscopy experimental parameters 
 
Cell fixation conditions were optimised with respect to cell type, fixation reagent, and 
incubation time and temperature. HEK 293T cells were fixed onto glass slides as well 
as treated Lab-TeK II Chamber Slides under three different conditions (Table 3.2). 
The subsequent cell viability and integrity was visually determined by light 
microscopy. The HEK 293T cells demonstrated a tendency to wash off or shrink when 
treated with methanol, or incubated with 3% formaldehyde for longer than 15 minutes. 
Incubation with 3% paraformaldehyde and 0.02% glutaraldehyde preserves external 
structures, but results in similar stability as 3% formaldehyde, which was chosen as 
the optimal reagent. Cells were also suspended in a drop of glycerol, which 
maintained the integrity of both cell types, but caused the cells to float in different 
planes of view causing difficulty when focussing on a single cell. Figure 3.6 illustrates 
the difference in cell viability under optimal and suboptimal transfection and fixation 
conditions. 
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Table 3.1: Optimisation of mammalian cell cotransfection experiments with subtype B and C 
pcDNA6.2/C-emGFP-Vpu and pDsRed-ER/Golgi/Mem. The table shows examples of plasmid 
ratios and transfection reagents used to increase transfection efficiency. Optimal efficiency is 























10 1:1 5.4 100 µl 
Polyfect 
8 20 25 cm3  
culture flask 
10 2:1 5.4 100 µl 
Polyfect 
8 20 
4 1:1 2.5 40 µl Polyfect 3 40 
2 1:1 2 20 µl Polyfect 3 50 
Single 
chamber 
slide 3 2:1 0.6 40 µl Polyfect 3 50 
4 1:1 0.25 2 µl lipofect 2 50 
4 1:1 0.25 4 µl Lipofect 2 60 




4 1:1 0.6 4 µl Lipofect. 2 80 
2 1:1 0.6 2 µl Lipofect 3 50 
4 1:1 0.6 4 µl Lipofect 3 60 
4 1:1 0.6 20 µl Polyect 3 50 
6 well plate 
4 1:1 0.6 40 µl Polyfect 3 10 
*Transfection efficiency was determined by manually counting cells with fluorescence as a percentage of the total number of 
cells on slide. 
 
Table 3.2: Optimisation of fixation conditions for preparation of cotransfected HEK 293T 
mammalian cells for confocal microscopy  
 





Ice cold  100 % 
Methanol 
10 min -20 °C 100% HEK 293T cells 
were shrunken and 
internal organelles 
difficult to distinguish. 
Precooled 3% 
Formaldehyde 
15 min Room temperature Some cells wash off, 





15 min Room temperature 60% cells wash off the 
slide. 
Glycerol Indefinitely Room temperature All cells are viable but 
float in different planes 
of view.  




Figure 3.6: HEK 293T cells treated under suboptimal (A), and optimal (B) transfection and fixing 
conditions, as viewed by confocal microscopy. HEK 293T cells in (A) were transfected using 
Polyfect reagent, and fixed with 100% methanol. Cells in (B) were transfected with 
Lipofectamine reagent and fixed with 3% formaldehyde. Transmitted light phase images were 




3.5.2 Subcellular localisation of subtype B and C Vphu proteins 
 
The three Vphu-emGFP recombinant plasmids were successfully cotransfected with 
pDsRed-ER, pDsRed-Mem or pDsRed-Golgi into HEK 293T cells to confirm the 
presence of Vpu at different subcellular compartments over time. Cells were fixed 
with 3% formaldehyde and examined at 24, 48 and 60 hours post cotransfection 
using a Zeiss Carv Axiovert 100M inverted confocal microscope. The images were 
sequentially acquired using the Plan-Neofluar 63x or 100x /1.30 Oil objective and 
superimposed in multitrack channel mode to show colocalisation. Representative 
digital images were collected and analysed using Axiovision 2.0 software. The cells 
were viewed immediately after the transfection reaction (0 hours) to ensure cell 
viability and to note background fluorescence, which was minimal. Transfection 
A B
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experiments for each subtype construct were repeated five or more times, and eight 
or more images were examined per slide. 
 
Optimised cotransfection reactions resulted in the successful expression of both 
subtype B and C Vphu-emGFP fusion proteins, and subcellular localisation proteins in 
at least 50% of HEK 293T cells (Figures 3.7, 3.8 and 3.9). The single colour channels 
show green pixels representing Vphu-emGFP expression, and red pixels representing 
the DsRed subcellular localisation proteins. Figures C, F, I, L, O, R, U, X and ¥ 
represent the overlay of the green (FITC) and red (PE) channels, which result in a 
yellow colour when the proteins have colocalised.  
 
Extensive analysis of cotransfections revealed that at 24 hours post-transfection 
(Figures 3.7.1-3, 3.8.1-3, and 3.9.1-3), the subtype C FV5 Vphu-emGFP protein was 
in the cytoplasm, with definite localisation at the ER and Golgi (Figure 3.7.1C, and 
3.7.2F), but not the plasma membrane (Figure 3.7.3I). The subtype C FV15 Vphu-
emGFP protein appeared to have weaker localisation at the ER and Golgi at 24 hours 
post-transfection (Figure 3.8.1C and 3.8.2F), and no plasma membrane localisation 
(Figure 3.8.3I). In contrast, the subtype B Vphu-emGFP protein had strong Golgi 




At 48 hours post-transfection (Figures 3.7.4-6, 3.8.4-6, and 3.9.4-6), FV5 Vphu-
emGFP was still strongly localised at the ER and Golgi (Figure 3.7.4L and 3.7.5O), 
but some protein was observed at the plasma membrane (Figure 3.7.6R, and arrows 
in Figure 3.7.5O). FV15 Vphu-emGFP displays ER, Golgi and plasma membrane 
localisation at 48 hours post-transfection (Figures 3.8.4L, 3.8.5O, and 3.8.6R). 
Subtype B Vphu-emGFP was clearly localised at the ER at 48 hours post-transfection 
(Figure 3.9.4L), with some fluorescence seen at the plasma membrane (Figure 
3.9.6R). At 60 hours post-transfection (Figures 3.7.7-9, 3.8.7-8, and 3.9.7-9), the 
Vphu-proteins appear as large accumulations in the shrunken HEK 293T cells. The 
FV5 Vphu-emGFP was observed at the plasma membrane (Figure 3.7.9¥), while 
FV15 and subtype B Vphu-emGFP showed ER-localisation at 60 hours post-
transfection (Figures 3.8.7U and 3.9.7U). A composite summary of this localisation 




Figure 3.7.1: Subcellular localisation of HIV-1 subtype C FV5 Vphu-emGFP at 24 hours post co-
transfection of HEK 293T cell with dsRed-ER as determined by confocal microscopy. Nuclei are 
stained blue. Size bars represent 10 microns in measurement (1000X). Single colour channels 
show FV5 Vphu-emGFP fluorescence in green (A) and dsRed-ER fluorescence in red (B). An 










Figure 3.7.2: Subcellular localisation of HIV-1 subtype C FV5 Vphu-emGFP at 24 hours post co-
transfection with pDsRed-Golgi as determined by confocal microscopy. Nuclei are stained blue. 
Size bars represent 10 microns in measurement (1000X). Single colour channels show FV5 
Vphu-emGFP fluorescence in green (D) and dsRed-Golgi fluorescence in red (E). An overlay of 






Figure 3.7.3: Subcellular localisation of HIV-1 subtype C FV5 Vphu-emGFP at 24 hours post co-
transfection with pDsRed-Mem as determined by confocal microscopy. Nuclei are stained blue. 
Size bars represent 10 microns in measurement (1000X). Single colour channels show FV5 
Vphu-emGFP fluorescence in green (G) and dsRed-Mem fluorescence in red (H). An overlay of 






Figure 3.7.4: Subcellular localisation of HIV-1 subtype C FV5 Vphu-emGFP at 48 hours post co-
transfection with pDsRed-ER as determined by confocal microscopy. Nuclei are stained blue. 
Size bars represent 10 microns in measurement (1000X). Single colour channels show FV5 
Vphu-emGFP fluorescence in green (J) and dsRed-ER fluorescence in red (K). An overlay of 






Figure 3.7.5: Subcellular localisation of HIV-1 subtype C FV5 Vphu-emGFP at 48 hours post co-
transfection with pDsRed-Golgi as determined by confocal microscopy. Nuclei are stained blue. 
Size bars represent 10 microns in measurement (1000X). Single colour channels show FV5 
Vphu-emGFP fluorescence in green (M) and dsRed-Golgi fluorescence in red (N). An overlay of 
these images (O) shows colocalisation in yellow. Arrows indicate Vphu-emGFP expression at 






Figure 3.7.6: Subcellular localisation of HIV-1 subtype C FV5 Vphu-emGFP at 48 hours post co-
transfection with pDsRed-Mem as determined by confocal microscopy. Nuclei are stained blue. 
Size bars represent 10 microns in measurement (1000X). Single colour channels show FV5 
Vphu-emGFP fluorescence in green (P) and dsRed-Mem fluorescence in red (Q). An overlay of 






Figure 3.7.7: Subcellular localisation of HIV-1 subtype C FV5 Vphu-emGFP at 60 hours post co-
transfection with pDsRed-ER as determined by confocal microscopy. Nuclei are stained blue. 
Size bars represent 10 microns in measurement (1000X) . Single colour channels show FV5 
Vphu-emGFP fluorescence in green (S) and dsRed-ER fluorescence in red (T). An overlay of 






Figure 3.7.8: Subcellular localisation of HIV-1 subtype C FV5 Vphu-emGFP at 60 hours post co-
transfection with pDsRed-Golgi as determined by confocal microscopy. Nuclei are stained blue. 
Size bars represent 10 microns in measurement (1000X). Single colour channels show FV5 
Vphu-emGFP fluorescence in green (V) and dsRed-Golgi fluorescence in red (W). An overlay of 






Figure 3.7.9: Subcellular localisation of HIV-1 subtype C FV5 Vphu-emGFP at 60 hours post co-
transfection with pDsRed-Mem as determined by confocal microscopy. Nuclei are stained blue. 
Size bars represent 10 microns in measurement (1000X). Single colour channels show FV5 
Vphu-emGFP fluorescence in green (Y) and dsRed-Mem fluorescence in red (Z). An overlay of 






Figure 3.8.1: Subcellular localisation of HIV-1 subtype C FV15 Vphu-emGFP at 24 hours post co-
transfection with pDsRed-ER as determined by confocal microscopy. Nuclei are stained blue. 
Size bars represent 10 microns in measurement (630X). Single colour channels show FV5 Vphu-
emGFP fluorescence in green (A) and dsRed-ER fluorescence in red (B). An overlay of these 






Figure 3.8.2: Subcellular localisation of HIV-1 subtype C FV15 Vphu-emGFP at 24 hours post co-
transfection with pDsRed-Golgi as determined by confocal microscopy. Nuclei are stained blue. 
Size bars represent 10 microns in measurement (630X). Single colour channels show FV5 Vphu-
emGFP fluorescence in green (D) and dsRed-Golgi fluorescence in red (E). An overlay of these 






Figure 3.8.3: Subcellular localisation of HIV-1 subtype C FV15 Vphu-emGFP at 24 hours post co-
transfection with pDsRed-Mem as determined by confocal microscopy. Nuclei are stained blue. 
Size bars represent 10 microns in measurement (630X). Single colour channels show FV5 Vphu-
emGFP fluorescence in green (G) and dsRed-Mem fluorescence in red (H). An overlay of these 






Figure 3.8.4: Subcellular localisation of HIV-1 subtype C FV15 Vphu-emGFP at 48 hours post co-
transfection with pDsRed-ER as determined by confocal microscopy. Nuclei are stained blue. 
Size bars represent 10 microns in measurement (1000X). Single colour channels show FV5 
Vphu-emGFP fluorescence in green (J) and dsRed-ER fluorescence in red (K). An overlay of 






Figure 3.8.5: Subcellular localisation of HIV-1 subtype C FV15 Vphu-emGFP at 48 hours post co-
transfection with pDsRed-Golgi as determined by confocal microscopy. Nuclei are stained blue. 
Size bars represent 10 microns in measurement (1000X). Single colour channels show FV5 
Vphu-emGFP fluorescence in green (M) and dsRed-Golgi fluorescence in red (N). An overlay of 






Figure 3.8.6: Subcellular localisation of HIV-1 subtype C FV15 Vphu-emGFP at 48 hours post co-
transfection with pDsRed-Mem as determined by confocal microscopy. Nuclei are stained blue. 
Size bars represent 10 microns in measurement (1000X). Single colour channels show FV5 
Vphu-emGFP fluorescence in green (P) and dsRed-Mem fluorescence in red (Q). An overlay of 






Figure 3.8.7: Subcellular localisation of HIV-1 subtype C FV15 Vphu-emGFP at 60 hours post co-
transfection with pDsRed-ER as determined by confocal microscopy. Nuclei are stained blue. 
Size bars represent 10 microns in measurement (1000X). Single colour channels show FV5 
Vphu-emGFP fluorescence in green (S) and dsRed-ER fluorescence in red (T). An overlay of 






Figure 3.8.8: Subcellular localisation of HIV-1 subtype C FV15 Vphu-emGFP at 60 hours post co-
transfection with pDsRed-Golgi as determined by confocal microscopy. Nuclei are stained blue. 
Size bars represent 10 microns in measurement (1000X). Single colour channels show FV5 





Figure 3.9.1: Subcellular localisation of HIV-1 subtype B Vphu-emGFP at 24 hours post co-
transfection with pDsRed-ER as determined by confocal microscopy. Nuclei are stained blue. 
Size bars represent 10 microns in measurement (1000X). Single colour channels show FV5 
Vphu-emGFP fluorescence in green (A) and dsRed-ER fluorescence in red (B). An overlay of 








Figure 3.9.2: Subcellular localisation of HIV-1 subtype B Vphu-emGFP at 24 hours post co-
transfection with pDsRed-Golgi as determined by confocal microscopy. Nuclei are stained blue. 
Size bars represent 10 microns in measurement (1000X). Single colour channels show FV5 
Vphu-emGFP fluorescence in green (D) and dsRed-Golgi fluorescence in red (E). An overlay of 






Figure 3.9.3: Subcellular localisation of HIV-1 subtype B Vphu-emGFP at 24 hours post co-
transfection with pDsRed-Mem as determined by confocal microscopy. Nuclei are stained blue. 
Size bars represent 10 microns in measurement (1000X). Single colour channels show FV5 
Vphu-emGFP fluorescence in green (G) and dsRed-Mem fluorescence in red (H). An overlay of 






Figure 3.9.4: Subcellular localisation of HIV-1 subtype B Vphu-emGFP at 48 hours post co-
transfection with pDsRed-ER as determined by confocal microscopy. Nuclei are stained blue. 
Size bars represent 10 microns in measurement (1000X). Single colour channels show FV5 
Vphu-emGFP fluorescence in green (J) and dsRed-ER fluorescence in red (K). An overlay of 






Figure 3.9.5: Subcellular localisation of HIV-1 subtype B Vphu-emGFP at 48 hours post co-
transfection with pDsRed-Golgi as determined by confocal microscopy. Nuclei are stained blue. 
Size bars represent 10 microns in measurement (1000X). Single colour channels show FV5 
Vphu-emGFP fluorescence in green (M) and dsRed-Golgi fluorescence in red (N). An overlay of 






Figure 3.9.6: Subcellular localisation of HIV-1 subtype B Vphu-emGFP at 48 hours post co-
transfection with pDsRed-Mem as determined by confocal microscopy. Nuclei are stained blue. 
Size bars represent 10 microns in measurement (1000X). Single colour channels show FV5 
Vphu-emGFP fluorescence in green (P) and dsRed-Mem fluorescence in red (Q). An overlay of 






Figure 3.9.7: Subcellular localisation of HIV-1 subtype B Vphu-emGFP at 60 hours post co-
transfection with pDsRed-ER as determined by confocal microscopy. Nuclei are stained blue. 
Size bars represent 10 microns in measurement (1000X). Single colour channels show FV5 
Vphu-emGFP fluorescence in green (S) and dsRed-ER fluorescence in red (T). An overlay of 






Figure 3.9.8: Subcellular localisation of HIV-1 subtype B Vphu-emGFP at 60 hours post co-
transfection with pDsRed-Golgi as determined by confocal microscopy. Nuclei are stained blue. 
Size bars represent 10 microns in measurement (1000X). Single colour channels show FV5 
Vphu-emGFP fluorescence in green (V) and dsRed-Golgi fluorescence in red (W). An overlay of 






Figure 3.9.9: Subcellular localisation of HIV-1 subtype B Vphu-emGFP at 60 hours post co-
transfection with pDsRed-Mem as determined by confocal microscopy. Nuclei are stained blue. 
Size bars represent 10 microns in measurement (1000X). Single colour channels show FV5 
Vphu-emGFP fluorescence in green (Y) and dsRed-Mem fluorescence in red (Z). An overlay of 












The HIV-1 subtype B and C Vpu accessory proteins, which are involved in CD4 
degradation and virion release, were found to localise to different cellular 
compartments (the ER/Golgi apparatus and plasma membrane, respectively) when 
compared at 48 hours (Pacyniak, Gomez et al. 2005). The localisation of the Vpu 
proteins has an impact on its function in the HIV-1 life cycle. This study confirmed 
these findings, and in addition showed that subtype B Vpu can localise to the plasma 
membrane and subtype C Vpu can localise to the ER/Golgi apparatus across the time 
course. Analysis of subcellular localisation was achieved by cloning representative 
subtype B and C vpu into an emerald-GFP reporter vector and monitoring the 
movement of these proteins in HEK 293T mammalian cells up to 60 hours.  
 
Two HIV-1 subtype C vpu genes were selected for this study because of the distinct 
N-terminal insertions (McCormick-Davis, Dalton et al. 2000; Scriba, Treurnicht et al. 
2001; Bell, Connell et al. 2007). Existing sequence data  distinguished 05ZAFV5 as 
having a six amino acid insertion at the N-terminus and a predicted protein length of 
86 amino acids (Bell, Connell et al. 2007). By contrast, 05ZAFV15 has a two amino 
acid insert at the N-terminus and is 82 amino acids in length. 05ZAFV5 was therefore 
selected as a representative subtype C isolate, and 05ZAFV15 was selected because 
it more closely resembled the representative 81 amino acid subtype B Vpu chosen for 
this study (NL4-3 isolate).  
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Comparison of the native and codon optimised Vpu sequences cloned into the 
pcDNA™6.2/C-emGFP-GW/TOPO® vectors showed identical predicted amino acid 
sequences, except for the presence of a V at position eight in the subtype B Vpu 
instead of a Q as observed in the wild-type NL4-3 strain (Figure 3.1, see Appendix F 
for single-letter amino acid code). Valine has a hydrophobic side chain instead of the 
hydrophilic group of glutamine. This change is not likely to impact on the protein’s 
ability to localise in the membrane since it may only contribute to the already 
hydrophobic TMD.  
 
Extensive sequence analysis and identification of known functional domains revealed 
that the NTD, the TMD, and the two α-helices of the C-terminal domain were all 
predicted to be intact (Figure 3.1). Importantly, the essential tryptophan in the TMD 
(position 28, in blue), the tyrosine in the hinge region (34-EYRK-37, in red), and the 
two serines involved in CK-II phosphorylation (56-EDSGNESEG-64, in green) were 
found to be conserved throughout the three isolates. The tryptophan is involved in ion 
channel gating, while the tyrosine has been shown to be essential for virion release 
and forms part of the structurally critical salt bridge between the TMD and CD 
(Cordes, Kukol et al. 2001; Sramala, Lemaitre et al. 2003; Candler, Featherstone et 
al. 2005).  
 
Besides the distinct subtype C NTD, two other disparate motifs can be singled out. 
The putative Golgi-retention signal, 79-LRLL-82 (Figure 3.1, in purple) is present in 
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and unique to the subtype C sequences. The subtype B sequence, however, has the 
sequence 79-HAPW-82 instead. An extra dileucine motif, 4-LLAR-7 is present in the 
longer NTD of 05ZAFV5. A longer NTD is present in about 60% of subtype C Vpu 
proteins (http://www.hiv.lanl.gov/ 2009) (Appendix G). This extra dileucine or another 
unidentified motif in the NTD may be involved in signalling the subtype C Vpu to 
different subcellular compartments.  
 
The potential extra CK-II phosphorylation site, 71-T(X)VD-74 (Figure 3.1, in 
turquoise), is also present in the subtype C isolates and observed to be TLVD in 
05ZAFV5 and TMVD in 05ZAFV15. This sequence is absent in subtype B, which 
instead harbours a glycine insertion at position 73 within the subtype B sequence, 71-
EMGVE-75. CK-II is a ubiquitous protein kinase, able to regulate metabolic pathways, 
signal transduction, as well as transcription, translation and replication (Guerra and 
Issinger 2008; Olsen and Guerra 2008; Yde, Olsen et al. 2008). It is a tetrameric 
holoenzyme (Niefind, Guerra et al. 1998) with the alpha and alpha prime subunits 
having a catalytic function, and the two beta subunits having a regulatory function 
(Guerra and Issinger 2008). Of significance is the localisation of the enzyme to the 
ER/Golgi apparatus (Niefind, Guerra et al. 2001). The presence of these different 
motifs implies a difference in function. 
 
That the function of Vpu in the viral replication cycle is based on its structure is well 
established for HIV-1 subtype B (Willey, Maldarelli et al. 1992; Schubert, Henklein et 
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al. 1994; Schubert, Ferrer-Montiel et al. 1996). The presence of Vpu at different 
cellular levels also informs its function. Its presence is required at the ER/TGN for 
interaction with CD4 via ßTrCP and the phosphorylation of its two essential serines in 
the CD (Jabbar 1995; Paul and Jabbar 1997). Vpu also enhances virion release, a 
function involving the binding of the TMD to tetherin, and its ability to insert into 
cellular membranes to form ion channels (Strebel, Klimkait et al. 1989; Schubert, 
Ferrer-Montiel et al. 1996; Paul, Mazumder et al. 1998). Assessing the presence of 
Vpu at different subcellular compartments may aid in elucidating the link between 
these functions. 
 
In order to explore differences in subcellular localisation, the selected subtype B and 
C vphu genes were successfully subcloned into the pcDNA™6.2/C-emGFP-
GW/TOPO® mammalian expression vector (Invitrogen). Confocal microscopy, as well 
as SDS-PAGE and Western blot analysis of HEK 293T cells at 24 hours post-
transfection with the Vphu-emGFP vectors confirmed the expression of the Vphu-
emGFP fusion proteins. The impact of the 27 kDa emGFP on the function of the 16 
kDa Vpu (resulting in a 43 kDa fusion protein) is considered to be minimal. Pacyniak 
et al. used an EGFP reporter system to study Vpu subcellular localisation and found 
that the fusion proteins were functional for CD4 degradation (Pacyniak, Gomez et al. 
2005). They also reported Golgi complex localisation of Vpu-EGFP, as well as Gag-
EGFP release from transfected cells, which corresponded exactly to the native 
subtype B Vpu function (Pacyniak, Gomez et al. 2005). Moreover, the EGFP alone 
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fractionated to the S100 division, while the Vpu-EGFP fractionated to the membrane 
enriched P100 section after ultracentrifugation (Pacyniak, Gomez et al. 2005). The 
reporter system used in the current study is based on this EGFP reporter system, and 
the subtype B construct was found to localise to the Golgi compartment. Accordingly, 
the emGFP is not expected to effect Vpu expression. 
 
Conversely, Pacyniak et al. did not use codon-optimised proteins in their study of Vpu 
localisation (Pacyniak, Gomez et al. 2005). Vpu is notoriously difficult to express in 
the absence of viral Tat and Rev, which are involved in the transcription and the 
translocation of the vpu RNA molecule from the nucleus to the cytoplasm (Nguyen, 
llano et al. 2004). Codon-optimisation stabilises the vphu mRNA in the nucleus, and 
thus allow for more efficient export via the chromosome region maintenance protein 1 
(CRM1)-independent nuclear export pathway (Nguyen, llano et al. 2004). Codon-
optimisation in this study led to good expression of the protein, with localisation 
matching that found by Pacyniak et al. (Pacyniak, Gomez et al. 2005). Subtype B 
expression appears to be more effective on the Western blot (Figure 3.5B) but no 
assumptions can be made about expression efficiency, as an expression control was 
not included. This can be included in future work.  
 
Pacyniak et al., reported subtype B Vpu ER/Golgi localisation, and subtype C Vpu 
localisation at all membranes, including the plasma membrane at 48 hours (Pacyniak, 
Gomez et al. 2005). The current study confirms the colocalisation of subtype B Vpu at 
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the ER/Golgi and the accumulation of the subtype C Vpu proteins at the plasma 
membrane at 48 hours. The average HIV replication cycle is thought to be about two 
and a half days. This study therefore looked at colocalisation data up to 60 hours 
post-transfection. Specifically, results from this study show that subtype B Vpu moves 
from the plasma membrane at 24 hours to the ER/Golgi at 48 hours, and is diffuse at 
60 hours, with areas of strong ER localisation. Subtype B Vpu may primarily bind 
tetherin at the plasma membrane, and redistribute it to the ER/Golgi where it also 
allows for the degradation of CD4.  
 
The typical subtype C Vpu from isolate 05ZAFV5 behaves differently, moving from 
the ER/Golgi at 24 hours to the plasma membrane at 48 hours, and is diffuse at 60 
hours with strong plasma membrane localisation. This implies that subtype C Vpu 
primarily acts to degrade CD4 at the ER/Golgi, and then moves to the plasma 
membrane to enhance virion release via ion channel formation, and/or to antagonise 
tetherin. The subtype C Vpu from isolate 05ZAFV15 with the shorter NTD has weak 
colocalisation with the ER/Golgi markers at 24 hours but at 48 hours, strong ER/Golgi 
and plasma membrane colocalisation is observed. The longer NTD of isolate 
05ZAFV5 may be responsible for this difference.  
 
The localisation at 60 hours for subtype B and C Vpu is diffuse and condensed. As a 
result, it is difficult to interpret this data but it may reflect the localisation of Vpu to a 
large majority of endomembranous compartments including the ER, the TGN, and 
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endosomes, as well as the plasma membrane late in the viral life cycle. Overall, this 
implies that a factor exists that allows subtype B Vpu to be targeted to the plasma 
membrane at 24 hours and to the ER/Golgi colocalisation at 48 hours, while the 
subtype C Vpu proteins are primarily at the ER/Golgi region with movement of some 
of the protein to the plasma membrane at 48 hours. 
 
This factor was originally proposed to lie within the CD by using subtype B and C Vpu 
chimeras where the CD of each were exchanged (Pacyniak, Gomez et al. 2005). The 
Mr values of the chimeras differed, indicating a structural difference between the 
subtype B and C Vpu CDs. Importantly, the subtype C Vpu containing the CD of a 
subtype B protein allowed for the targeting of the chimeric protein to the Golgi region 
at 48 hours (Pacyniak, Gomez et al. 2005). Deletion mutants of the subtype B Vpu 
CD then confirmed that the C-terminal 23 amino acids were sufficient for retention of 
the protein in the Golgi at 48 hours (Pacyniak, Gomez et al. 2005). This region, the 
second α-helical domain of the CD, was therefore suspected to harbour a Golgi-
retention signal. Remarkably, this region is the most divergent region in terms of 
sequence between subtype B and C (http://www.hiv.lanl.gov/ 2009), and as 
mentioned contains two subtype C-unique motifs, the potential CK-II phosphorylation 
site TMVD, and the dileucine motif, LRLL (Scriba, Treurnicht et al. 2001; Bell, Connell 
et al. 2007). Subtype C Vpu therefore has extra Golgi-retention signals, which may 
account for its presence at the ER/Golgi at 24 hours.  
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Protein signalling and trafficking in eukaryotic cells occurs via an elaborate network of 
membranous compartments (Cooper 2000). Proteins are synthesized on membrane-
bound ribosomes on the RER, and are directed to secretory or endocytic pathways in 
the cell via the ER and TGN (Lippincott-Schwartz, Roberts et al. 2000). Proteins 
harbour specific signal codes that are read by specialised ribonucleoprotein 
complexes (Hobman, Lemon et al. 1997). Proteins directed to the ER usually contain 
a stretch of hydrophobic residues that is cleaved off by a signal peptidase on the 
luminal side of the ER (Hobman, Woodward et al. 1995). Signal sequences within the 
protein are not cleaved, and the position of signal sequences and signal peptidase 
sequences determines retention in or retrieval from the ER (Hobman, Lemon et al. 
1997; Lippincott-Schwartz, Roberts et al. 2000).  
 
Post-translational modifications occur in the ER and later in the Golgi apparatus 
(Opat, van Vliet et al. 2001). Misfolded proteins are bound by chaperone proteins, 
and remain at the ER where they are eventually degraded via an ubiquitin-dependent 
pathway (Nehls, Snapp et al. 2000). The TGN functions as a sorting compartment 
directing proteins to the plasma membrane or lysosomes (Cooper 2000). Lysosomes 
contain acid hydrolases that degrade obsolete proteins, RNA, DNA, polysaccharides, 
and lipids (Cooper 2000). Lysosomes therefore represent a junction between the 
secretory pathway and the endocytic pathway (Cooper 2000).  
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The trafficking of membrane proteins to and from diverse cellular compartments 
usually involves tyrosine, dileucine, and monophenylalanine-based sorting signals 
(Kirchhausen 1999). CK-II phosphorylation is also important for the retrieval of some 
proteins. These motifs interact with adaptor complex proteins, AP-1, AP-2, and AP-3 
for endocytosis into clathrin-coated vesicles (Kirchhausen 1999; Janvier, Kato et al. 
2003). Tyrosine-based motifs generally interact with the µ4 subunit of the AP 
complexes (Bonifacino and Traub 2003). They are involved in endocytosis of 
membrane proteins from the plasma membrane (a G at position Y+1), or the targeting 
membrane proteins to lysosomes (an acidic residue at position Y+1) (Bonifacino and 
Traub 2003). Dileucine-based motifs also interact with the AP complexes, but with the 
hemi-complex formed by the small and large subunits (Janvier, Kato et al. 2003). The 
dileucine is important for efficient transport and expression of proteins at the plasma 
membrane. An acidic residue four, five, or six bases upstream of the dileucine motif 
confers more efficient internalisation and the sorting of membrane proteins to cellular 
sites such as the trans-Golgi network, endosomes, lysosomes, and the plasma 
membrane via the adaptor proteins (Janvier, Kato et al. 2003). The two subtype C 
Vpu proteins have a C-terminal dileucine motif with an upstream acidic residue (75-
DMGP/QLRLL-82, Figure 3.1). The Vpu from isolate 05ZAFV5 also has a dileucine 
within its NTD that is flanked by aspartic acids (1-MVDLLARVD-9, Figure 3.1). This 




Golgi-retention domains may also be heterogeneous or conformation dependent, and 
can involve transmembrane, or multimerization domains (Lippincott-Schwartz, 
Roberts et al. 2000). Glycosyltransferases for example, are retained in the Golgi by 
oligomerization to prevent their entry into transport vesicles (Sasai, Ikeda et al. 2001; 
Milland, Russell et al. 2002). Subtype B and C Vpu have several potential Golgi-
retention signals. Principally, there is a tyrosine-based membrane-proximal motif 
(EYRKL), and a CK-II phosphorylation region located between the α-helical 
cytoplasmic domains (ERADESGNESEGE) (Ruiz, Hill et al. 2008). Vpu is also known 
to oligomerize into a pentameric bundle (Moore, Zhong et al. 1998), suggesting 
retention of Vpu in the Golgi. The Vpu proteins in this study have both these potential 
Golgi-retention motifs, and the subtype C Vpu proteins have an additional CK-II site. 
This may influence the presence of all three proteins at the ER/Golgi throughout the 
analysed period, where it performs the important functions of CD4 down-regulation 
and retention of tetherin at the ER/Golgi. 
 
Ruiz et al., examined the overlapping tyrosine- (YXXΦ) and dileucine-based 
([D/E]XXXL[L/I]) motifs in the highly conserved membrane-proximal region of subtype 
C Vpu (EYRKLL) at 48 hours (Ruiz, Hill et al. 2008). The subtype C Vpu (from isolate 
BW16B01) has an EYRKLL sequence, as well as the C-terminal TMVD and LRLL 
sequences. It also has a five amino acid insert at the NTD similar to that of 05ZAFV5. 
Mutating the tyrosine residue to an alanine has no effect on transport to the plasma 
membrane, or on CD4 surface expression, but causes cytopathic viral stocks (Ruiz, 
 114
Hill et al. 2008). Altering the primary leucine to a glycine results in reduced Vpu 
expression at the plasma membrane, and five-fold more particles in vacuoles at the 
cell surface than the parental SHIVSCVpu as seen under an electron microscope (Ruiz, 
Hill et al. 2008). Mutating both the tyrosine and the primary leucine causes 
intermediate surface localisation of Vpu, less efficient replication, and significantly 
less effective downregulation of CD4 (Ruiz, Hill et al. 2008).  
 
Thus, the tyrosine residue is involved in increased viral release, the dileucine in Vpu 
surface expression and retention of virions at the cell surface, while both motifs are 
important for CD4 degradation at the ER/Golgi (Ruiz, Hill et al. 2008). This 
membrane-proximal hinge region forms a stabilising salt bridge between the TMD and 
CD. It is highly conserved across the group M viruses and the tyrosine is conserved in 
all group M Vpu sequences (http://www.hiv.lanl.gov/ 2009), and has been shown to 
be essential in enhancing virion release (Paul, Mazumder et al. 1998). The tyrosine is 
also conserved in the three proteins used in this study (Figure 3.1) suggesting they 
are functional for increasing virion release. Incredibly, a tyrosine-based signal in HIV-
1 Env initiates targeting of virions to the plasma membrane in polarised epithelial 
cells, and it concentrates viral assembly at one pole of infected lymphocytes 
(Cervantes-Acosta, Lodge et al. 2001).  
 
Dileucine motifs in the form of [D/E]XXXL[L/I] are recognised at the plasma 
membrane and at intracellular compartments for targeting to lysosomes (Janvier, 
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Kato et al. 2003). Membrane proximal dileucine motifs also mediate rapid 
internalisation and targeting of membrane proteins to endosomal and lysosomal 
compartments (Bonifacino and Traub 2003). Proximity of the Vpu EYRKLL motif to 
the TMD of the protein determines its involvement in endocytosis and/or lysosome 
targeting (Ruiz, Hill et al. 2008). The primary leucine is critical in signalling while an 
isoleucine at that position may cause the signal to be less potent. Approximately 80% 
of subtype C Vpu sequences have a membrane-proximal LL, LI, or LV (McCormick-
Davis, Dalton et al. 2000; Ruiz, Hill et al. 2008; http://www.hiv.lanl.gov/ 2009) 
(Appendix G). In contrast, about 95% of subtype B Vpu proteins have an isoleucine in 
the crucial primarily leucine position (EYRKIL), while only 5.2% have a LL, LI, or LV 
(Ruiz, Hill et al. 2008; http://www.hiv.lanl.gov/ 2009).  
 
In this study, the subtype C Vpu from isolate 05ZAFV5 has a membrane-proximal LV 
(EYRKLV) while the Vpu from isolate 05ZAFV15 has an unusual membrane-proximal 
LR sequence (EYRLR). The subtype B Vpu used in this study had an isoleucine in 
the primary position of the membrane proximal dileucine motif (EYRKIL). Predictably, 
it also lacked the additional CK-II phosphorylation site and the second α-helical 
dileucine (TMVD and LRLL in subtype C). This suggests that subtype B Vpu is not 
targeted for rapid internalisation from the plasma membrane, and is not taken up into 
lysosomes. This may account for the presence of subtype B Vpu at the plasma 
membrane at 24 hours post-transfection. Three subtype C Vpu proteins were used in 
the Pacyniak et al. study. All three proteins had a membrane proximal region with a 
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LL or LI motif, an extra CK-II site (TMVD) and an extra dileucine (LRLL) (Pacyniak, 
Gomez et al. 2005). C96-BW16B01 and C96-BW01B22 had a five amino acid insert, 
while 95IN-21301 had a one amino acid insert at the NTD (Pacyniak, Gomez et al. 
2005). These three proteins showed membrane localisation at 48 hours post-
transfection (Pacyniak, Gomez et al. 2005), in agreement with this study’s results.  
 
Ruiz et al. speculate over the reasons subtype C HIV-1 selects for the dileucine when 
it appears to reduce replication efficiency (Ruiz, Hill et al. 2008). This may give weight 
to studies showing that subtype C is evolving into a less virulent form (Arien, Abraha 
et al. 2005). Furthermore, the dileucine may interfere with the overlapping tyrosine-
based signal that is essential for enhancing virion release (Ruiz, Hill et al. 2008), and 
may therefore be important for tetherin interaction. Tetherin causes the retention of 
fully formed, mature virions at the plasma membrane, inducing their internalisation 
into endosomes (Neil, Eastman et al. 2006; Neil, Zang et al. 2008; Van Damme, Goff 
et al. 2008). The TMD of Vpu interacts with tetherin and CAML, thereby impeding 
their antiviral function (Neil, Zang et al. 2008; Varthakavi, Heimann-Nichols et al. 
2008). Mutating the TMD of a subtype B Vpu results in the protein not being able to 
colocalise with tetherin, whereas a truncated cytoplasmic tail (Vpu1-50) is still able to 
associate with tetherin (Neil, Zang et al. 2008).  
 
A recent study shows that mutating the conserved and charged arginine and lysine 
residues within the salt bridge region of a subtype B Vpu causes a decrease in 
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accumulation of the protein at the ER/TGN and late endosomal compartments, and is 
correlated to diminished HIV-1 virion release (Dube, Roy et al. 2009). This group also 
proposed that a second site important for TGN localisation is located in the second α-
helical region of the CD (Dube, Roy et al. 2009). This corresponds to all previous 
research noting the crucial nature of this region. There is a marked amount of Vpu-
tetherin colocalisation at the TGN, suggesting that localisation of Vpu to the TGN is 
vital to the antagonism of tetherin (Dube, Roy et al. 2009). Thus, the membrane-
proximal tyrosine, arginine and lysine residues are vital to tetherin antagonism, either 
by preventing its transport to the plasma membrane, or by sequestering the protein at 
intracellular compartments (Dube, Roy et al. 2009). These residues are conserved in 
all the Vpu proteins used in this study. However, the membrane-proximal dileucine 
motif may interfere with the tyrosine signal in subtype C, causing its presence at the 
plasma membrane at 48 hours. Subtype B Vpu does not harbour this overlapping 
dileucine and is able to move to the plasma membrane at 24 hours, and may 
therefore be more efficient at binding tetherin and transporting it back to the ER/Golgi 
at 48 hours.  
 
CAML also interacts with Vpu, and CAML-depletion eliminates the need for Vpu-
induced viral release (Varthakavi, Heimann-Nichols et al. 2008). There is speculation 
as to whether it is the mechanistic link between tetherin and Vpu, since both proteins 
operate within the membrane protein-internalisation pathway (Varthakavi, Heimann-
Nichols et al. 2008). CAML and a subtype B NL4-3 Vpu were found to colocalise in 
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the perinuclear region, with less colocalisation at peripheral vesicular structures 
(Varthakavi, Heimann-Nichols et al. 2008). Vpu requires functional recycling 
endosomes to exert its viral release function, but it must exit the pericentriolar 
endosome to enhance particle release (Varthakavi, Smith et al. 2006). Vpu and 
CAML may interact along the recycling pathway, as CAML does with EGFR (Tran, 
Russell et al. 2003). Vpu may prevent CAML from reaching the plasma membrane, or 
alternatively it may prevent CAML from directing the cycling of another factor involved 
in virus retention, such as tetherin (Varthakavi, Heimann-Nichols et al. 2008). 
Antagonism of CAML therefore requires cycling from the plasma membrane to the 
ER/Golgi, which corresponds to the timing of subtype B movement in this study. 
 
The differences in Vpu localisation are thus likely to have implications for the viral 
replication cycle and disease pathogenesis. Indeed, HXB2 Vpu is more efficient at 
down-regulating CD4 surface expression than four subtype C clinical isolates at 48 
hours (Hill, Ruiz et al. 2008). A SHIV construct with a subtype C Vpu (SHIVSCVpu) has 
decreased replication kinetics (that is, a delay of two days of p27 production), and a 
decreased ability to form syncytia in culture compared to the parental strain (SHIVKU-
1bMC33) (Hill, Ruiz et al. 2008). Inoculation of macaques with SHIVSCVpu also shows a 
more gradual loss of CD4+ T-cells, and early peak viral loads (in the first three weeks) 
are 10 fold less than macaques inoculated with the parental strain (Hill, Ruiz et al. 
2008). This study is striking in that the subtype of the Vpu protein is the only 
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difference between the SHIVs used to inoculate the macaques. As shown, the 
subtype also appears to be responsible for differences in subcellular localisation. 
 
T-cell activation is a major difference between SIV and HIV infections in their 
respective hosts. Non-pathogenic SIV infection lacks high-level immune activation, T 
cell turnover, and apoptosis (Apetrei, Robertson et al. 2004). This activation induced 
cell death (AICD) is present in HIV-1 and SIVcpz where the host fails to decrease the 
levels TCR-CD3 (Alimonti, Ball et al. 2003). In humans, very few CD8+/CTL and 
CD4+/T-helper cell responses are directed against Vpu and the antibody response is 
unknown (http://www.hiv.lanl.gov/content/immunology 2008). The best-defined CD8+ 
response is against the hinge region motif, EYRKLL that is recognised by HLA*3303 
(http://www.hiv.lanl.gov/content/immunology 2008). There are also six recognised 
epitopes that induce CTL responses, chiefly against the NTD and TMD. There is only 
one described CD4+/T-helper response, also against the TMD 
(http://www.hiv.lanl.gov/content/immunology 2008). In light of current data, Vpu can 
be considered a poorly immunogenic protein, which is remarkable as overcomes 
specific host factors. Then again, the effects of Vpu on virion release may have 
downstream effects on T-cell activation and the differences noted between macaques 
infected with constructs harbouring either a subtype B or C Vpu protein  (Ruiz, Hill et 
al. 2008). HIV-1 Subtype C may be evolving into a less virulent form (Arien, Abraha et 
al. 2005), and it has been proposed that this slower disease progression may 
increase transmission rates (Ruiz, Hill et al. 2008), accounting for the prevalence of 
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subtype C worldwide. The differences in Vpu localisation may also account for this 
decreased virulence. 
 
In summary, both the subtype B and C Vphu proteins used in this study had ER/Golgi 
localisation at 24, 48, and 60 hours post-transfection. The sequestering of CD4 
molecules at the ER/Golgi prevents its surface expression, thereby preventing its 
incorporation into budding virions, and the possibility of superinfection (Tanaka, Ueno 
et al. 2003; Wildum, Schindler et al. 2006). This highlights the importance of capturing 
CD4 at the ER/Golgi, making more CD4 available for proteasome degradation. The 
presence of extra dileucine motifs in subtype C, responsible for sorting to intracellular 
structures, may account for its initial localisation at the ER/Golgi at 24 hours. Subtype 
C Vphu may therefore accumulate earlier at the ER/Golgi and this may in turn 
enhance its ability to down-modulate newly synthesised CD4. Alternatively, subtype B 
Vphu may be localising to the plasma membrane earlier because of tyrosine 
signalling in its salt bridge region, and the lack of extra Golgi-retention signals in the 
C-terminal domain. Thus, subtype B Vphu may be able to bind tetherin or CAML at 
the plasma membrane at 24 hours before redistributing the antiviral proteins to the 
ER and TGN at 48 hours.  
 
The predominant localization of subtype C Vphu to the plasma membrane at 48 hours 
may lead to greater ion channel activity, resulting in enhanced virion release by 
membrane destabilization. However, with its membrane proximal dileucine interfering 
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with the tyrosine it may not be able to interact with AP complexes for sorting of 
tetherin/CAML to intracellular compartments. Future work should address whether the 
dileucine mutation causes more rapid CD4+ T-cell loss, and enhanced interaction 
with tetherin/CAML. The localisation of subtype C Vphu to the cell membrane at 48 
hours may also result in decreased replication kinetics and diminished pathogenesis, 
in line with the SHIV/Macaque models. In contrast, the subtype B Vphu may have 
increased CD4 downregulation because of localisation to the ER/Golgi region at 48 
hours. This may enhance the CD4-E3-ligase complex formation, and the retention of 
tetherin at intracellular membranes.  
 
Overall, the results strongly suggest that the replication cycle of subtype C is different 
from subtype B. Subtype B and C Vpu are known to differ structurally at the carboxy-
terminal end. This study emphasizes that the differences in the second α-helical CD 
may be related to the differences in subcellular localisation. The difference in 
subcellular localisation may affect CD4 downregulation in vitro, and CD4 T cell loss in 
vivo. HIV-1 subtype C also accounts for over 50% of worldwide HIV infection 
(www.unaids.org 2008). A clue to the marked difference in pathogenesis between 
these subtypes may therefore reside in the second α-helical domain of the Vpu CD. In 
conclusion, there is differential timing of translocation of HIV-1 subtype B and C Vpu 
to the ER/Golgi and plasma membrane compartments. It follows that differential 
timing of the cycling of tetherin/CAML, and of CD4 degradation, is likely to exist.  
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A few potential caveats in this study are apparent. Firstly, Vpu was not expressed 
from its original genomic position, under REV control, but from a codon-optimised 
gene under the control of a CMV promoter. In turn, the relative contribution of Env 
and Nef to localisation could not be taken into account. Nef is also involved in CD4 
downregulation and has a dileucine motif in its C-terminus that is required for this 
function (Aiken, Konner et al. 1994). Further, determining whether there are subtype 
differences in Nef’s ability to down-modulate CD4 during infection may be useful in 
accounting for these subtype specific differences in Vpu function. The interaction 
between these two proteins and their contribution to CD4 degradation should be 
determined in future studies. Also, since Vpu is not necessary for infection in HEK 
293T cells (Strebel, Klimkait et al. 1988) , it may not be crucial to overcome tetherin or 
CAML in these cells. 
 
Interestingly, Vpr-GFP studies have failed since Vpr-GFP is prone to site-specific 
proteolysis resulting in a mixture of intact and truncated forms with impaired function 
(Caly, Jans et al. 2008). The bioinformatics program, SignalP 3.0, predicts that signal 
peptidase activity for subtype C Vpu acts between positions 29 and 30 of the TM 
domain (TIA ^ YI, Figure 3.1) (http://www.cbs.dtu.dk/services/SignalP) (Brendtsen, 
Nielsen et al. 2004) . This suggests cleavage of the C-terminal from the N-terminal 
domain, and independent actions. Functional studies will be necessary to show if 
there is indeed proteolytic activity and whether this interferes with subcellular 
localisation. Current thinking, however, proposes the C-terminal stabilises the 
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transmembrane helix in the plasma membrane and remains functional within the 
cytoplasm (Sramala, Lemaitre et al. 2003). 
 
Future work may also include observing the subcellular localisation of the Vpu at time 
points earlier than 24 hours. Monitoring Vpu-induced CD4 down-modulation at each 
time point, possibly using flow cytometry, will also enhance this study. CD4 down 
modulation is noticeable 16 to 24 hours after infection of Jurkat cells with a NL4-3 
construct (Wildum, Schindler et al. 2006). The efficiency of infection of each subtype 
still needs to be clarified. Monkey data has shown that subtype C virus is less 
efficient, but HIV-1 subtype C is nonetheless the predominant virus worldwide. 
Creating chimeric 05ZAFV5/FV15 Vpu proteins containing the FV5 leader sequence 
may confirm whether the NTD has a role in protein trafficking. Site directed 
mutagenesis of the other signalling motifs would elucidate their impact on subcellular 
localisation. Quantitative image analysis could be performed on the confocal images 
to better define the extent of the colocalisation (Varthakavi, Smith et al. 2006).  
 
Overall, several researchers have established the essential role of Vpu in the HIV-1 
viral life cycle and impact on disease pathogenesis. The protein influences CD4 
degradation, viral particle budding, and antagonises the antiviral host proteins, 
tetherin, and CAML. Vpu is also unique to HIV-1 and SIV infecting humans and our 
recent ancestor, the chimpanzee, respectively. The expression of subtype B or C Vpu 
in the context of the same backbone has been shown to have a dramatically different 
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impact on the disease pathogenesis of infected macaques  (Ruiz, Hill et al. 2008). As 
ongoing research uncovers the precise interaction of Vpu-tetherin/CAML, and other 
as yet unidentified host proteins, novel antiviral treatment strategies will be 
uncovered. Results from this study highlight the significance of investigating subtype-
specific differences in Vpu function, and will lead to research probing the impact of 
these differences on subtype C-infected individuals. 
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Appendix B: Plasmid Maps 
 
 
Figure B1: EmGFP reporter plasmid, pcDNA 6.2/C-emGFP and positive control plasmid, pcDNA 

































Table B1: Symbol definitions for plasmid maps in Figures B1 and B2. 
Symbol Definition 
pCMV CMV promoter site 
T7 T7 promoter/priming site 
TOPO TOPO isomerase cloning sites 
EmGFP Gene encoding the emerald green fluorescent protein  
TK pa TK polyadenylation site 
Blast Blasticidin antibiotic gene 
Amp Ampicillin antibiotic gene 
SV40 pa SV40 polyadenylation signal 
pp UC   oo rr iii    pUC origin 
CATT    chloramphenicol acetyltransferase gene 




ER-targeting sequence of calrecticulin gene 
N-terminal 81 amino acids of human ß-1,4-galactosyltransferase 
N-terminal 20 amino acids of neuromodulin (GAP-43) that acts as a 
palmityolation signal 
KDEL ER-retention sequence, KDEL 
Kanamycin Kanamycin antibiotic resistance gene 
 129
Appendix C: Recipes and culture media 
 
C1  Bacterial transformations and cloning reactions 
 
C1.1 Luria Bertani Broth (LB) 
 
10 g tryptone, 5 g NaCl, 5 g yeast extract made up to 1 L with deionised distilled 
water (ddH2O). The solution was sterilised by autoclaving for 10 min at 121 °C. 
 
C1.2 Luria Bertani agar (LA) 
 
10 g tryptone, 5 g NaCl, 5 g yeast extract, and 15 g agar powder made up to 1 L with 
dH2O.  
 
C1.3 Ampicillin  
 
100 mg/ml: 1 g Amp dissolved in 10 ml 50% ethanol and stored at -20 °C. Add 1 µl/ml 
to cooled LB or LA.  
 
C1.4 Kanamycin  
 
50 mg/ml: 0.5 g Kanamycin powder dissolved in 10 ml ddH2O and stored at 4 °C. Add 
1 µl/ml to cooled LB or LA.  
 
C1.5 50X TAE 
 
242 g Tris dissolved in 500 ml ddH2O. To this add 100 ml o.5 M Na2EDTA (pH 8.0) 
and 57.1 ml glacial acetic acid. Adjust volume to 1 L with dH2O. The solution was 
stored at room temperature. 
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C1.6 Loading dye 
 
15 ml stock solution: 4.5 ml glycerol, 0.04 g bromophenol blue, in 10.5 ml ddH2O. 
 
C2 Culture Media 
 
C2.1 HEK 293T cells 
 
Propagation medium: DMEM (Sigma-Aldrich) supplemented with 10% heat 
inactivated fetal calf serum (FCS, Gibco, Invitrogen, NY, USA), 2 mM L-glutamine 
(Gibco, Invitrogen) and 10 µg/ml penicillin-streptomycin (Gibco, Invitrogen). 
 
Freeze medium: 90 % FCS, and 10% DMSO (Sigma-Aldrich). 
 
C3 SDS-PAGE and Western Blot solutions  
 
C3.1 4X Running gel buffer  
 
36.3 g Tris (FW 121.1) dissolved in 150 ml ddH2O and adjusted to pH 8.8 with 
hydrochloric acid (HCL). Made up to 200 ml with ddH2O and stored at 4 °C for up to 
three months. 
 
C3.2 4X Stacking gel buffer (0.5 M, Tris-Cl, pH 6.8) 
 
3 g Tris dissolved in 40 ml ddH2O and adjusted to pH 6.8 with HCL. Made up to 50 ml 
with ddH2O and stored at 4 °C for up to three months. 
 
 
C3.3 5X Tank buffer 
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144.13 g 196 mM glycine, 10 g 0.1 % SDS, 30.28 g 50 mM Tris made up to 2 L with 
ddH2O. Solution stored at room temperature for a month. 
 
C3.4 Transfer buffer 
 
200 ml 20% methanol and 200 ml 5X Tank buffer, dissolved in 500 ml with ddH2O. 
Made up to 2 L with ddH2O and stored at room temperature for a month. 
 
C3.5 2X SDS-PAGE sample buffer 
 
1 ml 1.5 M Tris (pH 6.8), 0.6 ml 20% SDS, 3 ml filter sterilised glycerol, 1.5 ml ß-
mecaptoethanol, 0.18 mg bromophenol blue.  
 
C3.6 10% Ammonium persulphate 
 
0.1 g Ammonium persulphate (APS) made up to 1 L with ddH2O.  
 
C3.7 Tris-buffered saline solution (TBS) 
 
125 mM NaCl, 25 mM Tris pH 8.3. 
 
C3.8 Tween-TBS (T-TBS) 
 




C3.9 Blocking buffer 
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5 g skim milk powder in 100 ml T-TBS 
 
C3.10 Destain solution (40% methanol, 7% acetic acid) 
 
400 ml methanol, 70 ml ecetic acid, made up to 1 L with ddH2O and stored at room 
temperature. 
 
C3.11 Coomassie stain (Coomassie Brilliant Blue R250, 40 % methanol, 7% 
acetic acid) 
 
0.5 g Coomassie Brilliant Blue R250 dissolved in 800 ml methanol. 140 ml acetic acid 
added and made up to 2 L with ddH2O. Stored at room temperature for up to six 
months. 
 
C4: Confocal microscopy solutions 
 
Dapi counterstain solution 
 
For a 5 mg/ml stock solution, add 10 mg Dapi powder to 2 ml dimethylformamide 
(DMF). For a 100 ng/ml working solution, add 2 µl Dapi stock solution to 100 ml PBS. 
Store working solution at 4 °C wrapped in aluminum foil.  
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Figure D1: (A) Roche DNA molecular weight marker X (0.07 – 12.2 kpb). Marker used for the size 











Appendix E: Summary of subtype B and C Vphu subncellular localizatio 
 
Table E1: Composite summary of subtype B and C Vphu localisation data as visualised by 
confocal microscopy.  
 24 hours 48 hours 60 hours* 
ER Weak Strong Strong 
Golgi Strong Weak Intermediate  
Subtype Vphu 
Membrane Strong Weak Intermediate  
ER Strong Strong Intermediate  
Golgi Strong Strong Intermediate  
05ZAFV5 Vphu 
Membrane None Weak Strong 
ER Weak Strong Strong 
Golgi Weak Strong Intermediate  
05ZAFV15 Vphu 
Membrane None Strong Intermediate  
* Vphu protein appears as large accumulations in relatively shrunken cells. Indicated localisation is 
observed as the most intense fluorescence. 
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Appendix F: The single-letter amino acid code 
 
 
Table F1: The single-letter amino acid code with associated abbreviation. 
Single-letter Amino acid abbreviation 
G Glycine Gly 
A Alanine Ala  
L Leucine Leu 
M Methionine Met 
F Phenylalanine Phe 
W Tryptophan Trp 
K Lysine Lys 
Q Glutamine Gln 
E Glutamic acid Glu 
S Serine Ser 
P Proline  Pro  
V Valine  Val  
I Isoleucine Ile 
C Cysteine  Cys  
Y Tyrosine Tyr  
H Histidine  His  
R Arginine  Arg 
N Asparagine  Asn  
D Aspartic acid Asp 
T Threonine  Thr  
 136
Appendix G: Alignment of all the HIV-1 Subtype C Vpu amino acid sequences available from Los Alamos. 
                                                                                                                           
                      *        20         *        40         *        60         *        80         *       100          
C.ZA.2004. : MVTPSEVGVIAAFILALILAIV-VWTIVYLEYRKIVKQRKIDWLIERIRERAEDSGNESEGDTEELAAMVD--MG--QLRLLDVNGV*---------------- : 82 
C.ZM.2002. : MVDYIAIGV-GALIVALIIAIV-VWTIAYIEYRKLLRQRKIDWLIKRIRERAEDSGNESEGDNEELATMVD--MG--QLRLLDVNNL*---------------- : 81 
C.ZA.2004. : MVDFIAIGV-GALIVAFIIAIV-VWTIAYLEYRKLLRQKRIDRLIERIRERAEGSGNESEGDTEELSTMVD--MG--NLRLLDVNNL*---------------- : 81 
C.BW.1996. : MLEL-IA-KI-DY-RLGG-GALIVALSIAIV-VWIIAYIEYKKLIRQRRINWLIERIRERAEDSGNESEGDTEELSTMVD--MG--HLRLLDDNAL*------- : 86 
C.BW.1996. : MLEL-IA-KI-DY-RLGV-GALIVALSIAIV-VWIIAYIEYKKLIRQRKINWLIERIRERAEDSGNESEGDTEELSTMVD--MG--HLRLLDDNAL*------- : 86 
C.BW.1996. : MLEL-VA-KV-DY-RLGV-GALIVALSIAIV-VWIIAYIEYKKLIRQRRVNWLIEGIRERAEDSGNESEGDTEELSTMVD--MG--HLRLLDDNAL*------- : 86 
C.IN..VB39 : ML-DY-KLGV-GAVIVALILAIV-VWIIVFIEYRKLVAQRKIDWLIKRIRERAEDSGNESEGDTEELSMLVD--MG--HLRLLDVNDL*--------------- : 80 
C.IN..VB39 : ML-DY-KLGV-GAVIVALILAIV-VWIIVFIEYRKLVAQRKIDWLIKRIRERAEDSGNESEGDTEELSMLVD--MG--HLRLLDVNDL*--------------- : 80 
C.IN..VB49 : MV-DYIQLGV-GALIVAFIIAIV-VWTIAYLEYRKWLRQRKIDRLIERIRERAEDSGNESEGDTEELSAMVD--MG--HLRLLDDNDL*--------------- : 81 
C.IN..VB49 : MV-DYIQLGV-GALIVAFIIAIV-VWTIAYLEYRKWLRQRKIDRLIERIRERAEDSGNESEGDTEELSAMVD--MG--HLRLLDDNDL*--------------- : 81 
C.IN..VB49 : MV-DYIQLGV-GALIVAFIIAIV-VWTIAYLEYRKWLRQRKIDRLIERIRERAEDSGNESEGDTEELSAMVD--MG--HLRLLDDNDL*--------------- : 81 
C.ZA.2004. : MLDL-LA-RV-DY-RLGV-GAFIVALIIAIV-VWIIAYIEYRKWLRQRKINWLIERIRERAEDSGNESEGDTEELSTLVD--ME--HLRLLDVNNG*------- : 86 
C.ZA.1998. : MLDL-LA--------IGV-GALIVALIIAIV-VWTIVYIEYRKLLRQKRIDWLIKRIRERAEDSGNESEGDTEELSTMVD--MG--HLRLLDVNDL*------- : 81 
C.ZA.1998. : MLDL-LA--------IGV-GALIVALIIAIV-VWTIVYIEYRKLLRQKRIDWLIKRIRERAEDSGNESEGDTEELSTMVD--MG--HLRLLDVNDL*------- : 81 
C.ZA.1998. : MLNL-LA-RV-DY-RIGV-GALTVALIIAIV-VWTIVYIEYRKLLRQKRIDWLIKRIRERAEDSGNESEGDTEELSTMGD--MG--HLRLLDVHDL*------- : 86 
C.ZA.2004. : MLDL-IG-KV-GY-RIGV-GALIVALIIAIV-VWTIVYIEYRKLLRQKRIDWLIKRIRERAEDSGNESEGDNEELSTMVD--MG--HLRLLDVIDL*------- : 86 
C.BW.2000. : MLDL-LA-GV-DY-RIGV-GAFLVALSIAIV-VWTIVYIEYRKLLRQKRIDRLIERIRERAEDSGNESEGDIEELSTMVD--MG--HLRLLDVNDV*------- : 86 
C.ZA.1998. : MLDL----KV-DY-RLAV-GAFIIALILAII-VWTIAYIKYRKVVRQKKIDWLVKRIKERAEDSGNESDGDTEELSTMVD--MG--HLRLLDANDL*------- : 84 
C.ZA.2005. : MLSL-LY-KV-DY-RIGV-GALVIALFLARI-VWTIAYLEYRKLSRQKKIDWLVKRIRERAEDSGNESEGDAEELSTMVD--MG--HLRLLDDNAL*------- : 86 
C.YE.2002. : MLDL-LA-KV-DY-RIGI-AAFVVALIIAII-VWTIAYIEYRKLVIQRKIDWLVKRIRERAEDSGNESDGDTEELSTMVD--MG--HLRLLDINDL*------- : 86 
C.FI.1992. : MFDL-TE-RV-DY-RLGV-GALIVALIIAII-VWTIAYIEYRKLLRQRKIDWLVKRIRERAEDSGNESEGDTEELSTMVD--MG--HLRLLDANDL*------- : 86 
C.TZ.1998. : MLDL-SA-RV-DY-RLGV-GALLVALIIAIV-VWTIVYIEYKKLVRQRRIDWLIKRIRERAEDSGNESDGDTEELSTMVD--MG--HLRLLDVNEL*------- : 86 
C.TZ.1997. : MLDL-TA-KV-DY-RLGV-GALIVALIIAIV-VWTIAYIEYRKLLRQRKIDCLIKRIRERAEDSGNESDGDTEELSTMVD--MG--HLRLLDVNDL*------- : 86 
C.ZA..99ZA : MLDL-LA-RV-DY-RLGV-GALIVALIIAIV-VWIIAYIEYRKLLRQRKIDWLIKRIRERAEDSGNESDGDTEELSTMVD--MG--HLRLLDVNDL*------- : 86 
C.KE.1995. : MLDL-IA-RV-DY-RLGV-GALIVALILAIV-VWIIAYLEYRKLVRQRKIDWLIKRIRERAEDSGNESDGDTEELSTMVE--VG--HLRLLDVNDL*------- : 86 
C.BW.1998. : MVVL-GE-KE-IY-ILGI-GALIVALIIAIV-VWSIAYIEYRKLVRQRRIDQLIKRIGERAEDSGNESDGDTEELSTLVD--MG--HLRLLDDNEL*------- : 86 
C.BW.2000. : MLGL-SE-KA-GY-ALGV-GALIVALIIVIV-VWTIVYIEYRKLVRQRKID*LIKRIRERAEDSGNESDGDTEELSTMVD--MG--NLRLLDVNDL*------- : 85 
C.ZA.2003. : MLDL-IE-RV-DY-RLGI-GALIVALIIAIV-VWTIAYIEYRKLVRQRKIDWLVKRIRERAEDSGNESDGDTEELSTMVD--MG--RLRLLDVNDL*------- : 86 
C.ZA.2003. : MLGL-PE-RV-DY-RLGV-GALIIALVIAIV-VWTIVYIEYRKLLRQRKINWLAKESGKEQKTVAMRVMGILRSCQQWW--IWG--GLGFWMF-MIY------- : 86 
C.ZA.2003. : MLGL-LE-RV-DY-RLGV-GALIIALVIAIV-VWIIAYIEYRKLLRQRKINWLAKRIRERAEDSGNESDGDIEELSTMVD--MG--RLRLLDANDV*------- : 86 
C.ZA.2004. : MVDF-TE-RV-DY-RIGV-GALIIALSIAIV-VWIIVYIEYRKLLRQKRIDWLAKRIRERAEDSGNESGGDIEELSTMVD--MG--QLRLLDVHDL*------- : 86 
C.TZ.2001. : MVDF-IA-SV-DY-RLGI-GALIIALLIVIV-VWTIVYIEYRKLVRQRKINWLIKRIRERAEDSGNESDGDTEELSEMVD--MG--RLGLLDANDV*------- : 86 
C.ZA.2000. : MVNW-AA-RV-DY-RLGV-GALIIALIIAIV-VWTIVYIEYRKLVRQRRIDWLIERIRERAEDSGNESEGDTEELGTMVD--LG--HLRLLDINGV*------- : 86 
C.ZA.2000. : MVNW-AA-RV-DY-RLGV-GALIIALIIAIV-VWTIVYIEYRKLVRQRRIDWLIERIRERAEDSGNESEGDTEELGTMVD--LG--HLRLLDINGV*------- : 86 
C.ZM.2002. : MINF-AA-RV-DY-RVGV-AAFTIALIIAIV-VWIIVYLE---LVRQRKIDQLIIRIREREEDSGNESEGDIEELSTMVD--MG--QLRLLDGNGL*------- : 83 
C.BW.2000. : MVDW-TK-KS-RL-*NSS-SSIYSSSNHSNS-CMDHSIYRI*EIKKTKKNKLVN*KN*RKSRRQWQRE*WGSGGIGNNGG--YG--AS*AFGC**FV------- : 79 
C.BW.2000. : MIDW-TE-QV-DY-RIAI-VIIYSSSNHSNS-YMDLSIYRI*EIVKTKKNRLVN*KN*RKGRRQWQ*E*WGS*GTGHHGG--FG--AS*AFGC**FV------- : 78 
C.BW.1996. : MIDW-TA-RV-DY-RVAV-V-AFIVALILAIIVWIIAYLEYRKLSKQRKIDCLIKRIRERAEDSGNESDGDQEELATMVD--MG--RLRLLD-TNDL*------ : 86 
C.BW.1998. : MSNW-TA-RV-DY-RIAI-A-AFIVALIIAIVVWTIVYIEYRKLSRQRKIDRLIKRIRERAEDSGNESDGDQDELATMVD--MG--HLRLLD-VNDL*------ : 86 
C.ZM.2003. : ML-EL-DY-KIAI-AALIVALIIAIV-VWTIVYIEYRKLVRQRKIDWLIKRIRERAEDSGNESDGDQEELSTMVD--MG--HLRLLGAIDL*------------ : 82 
C.ZM.2003. : ML-EL-DY-KIAI-AALIVALIIAIV-VWTIVYIEYRKLVRQRKIDWLIKRIRERAEDSGNESDGDQEELSTMVD--MG--HLRLLGAIDL*------------ : 82 
C.ZM.2003. : ML-EL-DY-KIAI-AALIVALIIAIV-VWTIVYIEYRKLVRQRKIDWLIKRIRERAEDSGNESDGDQEELSTMVD--MG--HLRLLGAIDL*------------ : 82 
C.ZM.2003. : ML-EL-DY-KIAI-AALIVALIIAIV-VWTIVYIEYRKLVRQRKIDWLIKRIRERAEDSGNESDGDQEELSTMVD--MG--HIRLLGAIDL*------------ : 82 
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C.ZM.2003. : ML-EL-DY-KIAI-AALIVALIIAIV-VWTIVYIEYRKLVRQRKIDWLIKRIRERAEDSGNESDGDQEELSTMVD--MG--HIRLLGAIDL*------------ : 82 
C.ZM.2003. : ML-EL-DY-KIAI-AALIVALIIAIV-VWTIVYIEYRKLVRQRKIDWLIKRIRERAEDSGNESDGDQEELSTMVD--MG--HIRLLGAIDL*------------ : 82 
C.ZM.2003. : ML-EL-DY-KIAI-AALIVALIIAIV-VWTIVYIEYRKLVRQRKIDWLIKRIRERAEDSGNESDGDQEELSTMVD--MG--HIRLLGAIDL*------------ : 82 
C.ZM.2003. : ML-EL-DY-KIAI-AALIVALIIAIV-VWTIVYIEYRKLVRQRKIDWLIKRIRERAEDSGNESDGDQEELSTMVD--MG--HIRLLGAIDL*------------ : 82 
C.ZM.2003. : ML-EL-DY-KIAI-AALIVALIIAIV-VWTIVYIEYRKLVRQRKIDWLIKRIRERAEDSGNESDGDQEELSTMVD--MG--HIRLLGAIDL*------------ : 82 
C.ZM.2003. : ML-EL-DY-KIAI-AALIVALIIAIV-VWTIVYIEYRKLVRQRKIDWLIKRIRERAEDSGNESDGDQEELSTMVD--MG--HIRLLGAIDL*------------ : 82 
C.ZM.2003. : ML-EL-DY-KIAI-AALIVALIIAIV-VWTIVYIEYRKLVRQRKIDWLIKRIRERAEDSGNESDGDQEELSTMVD--MG--HIRLLGAIDL*------------ : 82 
C.ZM.2003. : ML-EL-DY-KIAI-AALIVALIIAIV-VWTIVYIEYRKLVRQRKIDWLIKRIRERAEDSGNESDGDQEELSTMVD--MG--HIRLLGAIDL*------------ : 82 
C.ZM.2003. : ML-EL-DY-KIAI-AALIVALIIAIV-VWTIVYIEYRKLVRQRKIDWLIKRIRERAEDSGNESDGDQEELSTMVD--MG--HIRLLGAIDL*------------ : 82 
C.ZM.2003. : ML-EL-DY-KIAI-AALIVALIIAIV-VWTIVYIEYRKLVRQRKIDWLIKRIRERAEDSGNESDGDQEELSTMVD--MG--HIRLLGAIDL*------------ : 82 
C.ZM.2003. : ML-EL-DY-KIAI-AALIVALIIAIV-VWTIVYIEYRKLVRQRKIDWLIKRIRERAEDSGNESDGDQEELSTMVD--MG--HIRLLGAIDL*------------ : 82 
C.ZM.2003. : ML-EL-DY-KIAI-AALIVALIIAIV-VWTIVYIEYRKLVRQRKIDWLIKRIRERAEDSGNESDGDQEELSTMVD--MG--HIRLLGAIDL*------------ : 82 
C.ZM.2003. : ML-EL-DY-KIAI-AALIVALIIAIV-VWTIVYIEYRKLVRQRKIDWLIKRIRERAEDSGNESDGDQEELSTMVD--MG--HIRLLGAIDL*------------ : 82 
C.ZM.2003. : ML-EL-DY-KIAI-AALIVALIIAIV-VWTIVYIEYRKLVRQRKIDWLIKRIRERAEDSGNESDGDQEELSTMVD--MG--HIRLLGAIDL*------------ : 82 
C.ZM.2003. : ML-EL-DY-KIAI-AALIVALIIAIV-VWTIVYIEYRKLVRQRKIDWLIKRIRERAEDSGNESDGDQEELSTMVD--MG--HIRLLGAIDL*------------ : 82 
C.ZM.2003. : ML-EL-DY-KIAI-AALIVALIIAIV-VWTIVYIEYRKLVRQRKIDWLIKRIRERAEDSGNESDGDQEELSTMVD--MG--HIRLLGAIDL*------------ : 82 
C.ZM.2003. : ML-EL-DY-KIAI-AALIVALIIAIV-VWTIVYIEYRKLVRQRKIDWLIKRIRERAEDSGNESDGDQEELSTMVD--MG--HIRLLGAIDL*------------ : 82 
C.ZM.2003. : ML-EL-DY-KIAI-AALIVALIIAIV-VWTIVYIEYRKLVRQRKIDWLIKRIRERAEDSGNESDGDQEELSTMVD--MG--HIRLLGAIDL*------------ : 82 
C.ZM.2003. : ML-EL-DY-KIAI-AALIVALIIAIV-VWTIVYIEYRKLVRQRKIDWLIKRIRERAEDSGNESDGDQEELSTMVD--MG--HIRLLGAIDL*------------ : 82 
C.ZM.2003. : ML-EL-DY-KIAI-AALIVALIIAIV-VWTIVYIEYRKLVRQRKIDWLIKRIRERAEDSGNESDGDQEELSTMVD--MG--HIRLLGAIDL*------------ : 82 
C.ZM.2003. : ML-EL-DY-KIAI-AALIVALIIAIV-VWTIVYIEYRKLVRQRKIDWLIKRIRERAEDSGNESDGDQEELSTMVD--MG--HIRLLGAIDL*------------ : 82 
C.ZM.2003. : ML-EL-DY-KIAI-AALIVALIIAIV-VWTIVYIEYRKLVRQRKIDWLIKRIRERAEDSGNESDGDQEELSTMVD--MG--HIRLLGAIDL*------------ : 82 
C.ZM.2003. : ML-EL-DY-KIAI-AALIVALIIAIV-VWTIVYIEYRKLVRQRKIDWLIKRIRERAEDSGNESDGDQEELSTMVD--MG--HIRLLGAIDL*------------ : 82 
C.ZM.2003. : ML-EL-DY-KIAI-AALIVALIIAIV-VWTIVYIEYRKLVRQRKIDWLIKRIRERAEDSGNESDGDQEELSTMVD--MG--HIRLLGAIDL*------------ : 82 
C.ZM.2003. : ML-EL-DY-KIAI-AALIVALIIAIV-VWTIVYIEYRKLVRQRKIDWLIKRIRERAEDSGNESDGDQEELSTMVD--MG--HIRLLGAIDL*------------ : 82 
C.ZM.2003. : ML-EL-DD-KIAI-AALIVALIIAIV-VWTIVYIEYRKLVRQRKIDWLIKRIRERAEDSGNESDGDQEELSTMVD--MG--HIRLLGAIDL*------------ : 82 
C.ZM.2003. : ML-EL-DY-KIAI-AALIVALIIAIV-VWTIVYIEYRKLVRQRKIDWLIKRIRERAEDSGNESDGDQEELSTMVD--MG--HIRLLGAIDL*------------ : 82 
C.ZM.2003. : ML-EL-DY-KIAI-AALIVALIIAIV-VWTIVYIEYRKLVRQRKIDWLIKRIRERAEDSGNESDGDQEELSTMVD--MG--HIRLLGAIDL*------------ : 82 
C.ZM.2003. : ML-EL-DY-KIAV-AALIVALIIAIV-VWTIVYIEYRKLVRQRKIDWLIKRIRERAEDSGNESDGDQEELSTMVD--MG--HLRLLGAIDL*------------ : 82 
C.ZM.2003. : ML-EL-DY-KIAV-AALIVALIIAIV-VWTIVYIEYRKLVRQRKIDWLIKRIRERAEDSGNESDGDQEELSTMVD--MG--HLRLLGAIDL*------------ : 82 
C.BW.1999. : ML-EL-DY-RIGI-AAFIIALIIAIV-VWTIVYIEYRKLRRQRKIDRLIERIRERAEDSGNESDGDQEELSAMVD--MG--HLRLLDVNDL*------------ : 82 
C.AR.2003. : MINL-TD-RV-DY-RIGI-AAFLVALLIAIV-VWIIVYIEYRKLVRQRRIDWLIKRIRERAEDSGNESEGDTEELGTMVD--ME--HLRLLDVNDL*------- : 86 
C.BW.2000. : MIDL-SA-RV-DY-RIGV-AAFIIALIIAIV-VWTIVYIEYRKLLRQRKINWLIERIRERAEDSGNESEGDTEELATMVD--MG--HLRLLHDNNL*------- : 86 
C.TZ.2001. : MLDL-IA-RV-DY-RVGV-VAILIALIIAIV-VWTIVYIEYRKLVKQTKINRLIKRIRERTEDSGNESEGDMEELSTLVD--ME--HLGLLDVNEL*------- : 86 
C.ZA.2004. : MISL-LA-RI-DY-RIGI-AALLIALIIAIV-VWTIVYLEYRKLVKQRKIDWLIKRIRERAEDSGNESERDTEELSTMVD--MG--HLRLLDVNDL*------- : 86 
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C.ZA.1998. : MLSF--LEKV-DY-EIGV-AAFIIALIIAIV-VWIIVYIEYRKLLRQKRIDWLIERIRERAEDSGNESDGEQEELSTMVD--MG--NLRLLDANGW*------- : 86 
C.BW.1996. : MVDL--LAKV-DY-KIAV-AAFIIALIIAIV-VWIIVYVEYRKLVKQRKIDWLIERIRERAEDSGNESDGDHEELSTMVD--MG--HLRLLDANDL*------- : 86 
C.BW.1996. : MVDL--LAKV-DY-KIAV-AAFIIALIIAIV-VWIIVYVEYRKLVKQRKIDWLIERIRERAEDSGNESDGDHEELSTMVD--MG--HLRLLDANDL*------- : 86 
C.BW.1996. : MVDL--LAKV-DY-RIAV-AAFIIALIIAII-VWTIVYVEYRKLVKQRKIDWLIERIRERAEDSGNESDGDHEELSTMVD--MG--HLRLLDANDL*------- : 86 
C.ZA.2004. : MVDF--LARV-DY-RVGV-AAIIVALILVIV-VWIIVYIEYRKLSKQRKIDWLIERIRERAEDSGNESDGDQEELSTLVD--MG--HLRLLDVNDL*------- : 86 
C.ZA.1998. : MLDLNLLARV-DY-RVGV-AALLIALIIAVV-VWTIAYIEYRKLLRQRRIDKLIERIRERAEDSGNESDGDQEELSTMVD--MG--HLRLLGAYDL*------- : 88 
C.ZA.1998. : MLDLNLLARV-DY-RVGV-AALLIALIIAIV-VWTIAYIEYRKLLRQRRIDKLIERIRERAEDSGNESDGDQEELSTMVD--MG--HLRLLGAYDL*------- : 88 
C.ZA.1998. : MLDLNLLARV-DY-RVGV-AALLIALIIAIV-VWTIAYIEYRKLLRQRRIDKLIERIRERAEDSGNESDGDQEELSTMVD--MG--HLRLLGAYDL*------- : 88 
C.TZ.2001. : MVDL---TKI-DY-RLGV-GALIVALILAII-VWTIAYIEYRKLLRQIKIDKLIERIRERAEDSGNESDGDKEELATMED--VG--HLRLLDAYDL*------- : 85 
C.ZA.1998. : MVDL--LIEI-DY-RLGV-GALIVALIITII-VWTIAYLEYRKLQRQRKIDRLIERIRERAEDSGNESEGDAEELSTMVD--MG--NLRLLDVNDL*------- : 86 
C.ZA.2004. : MLDF--LAQV-DY-RIGV-GALIVALIIAII-VWTIAYLEYRKLKRQRKIDWLIERIRERAEDSGNESDGDHEELSTMVD--MG--HLRLLDVNDL*------- : 86 
C.FI.1993. : MLGL--IAKV-DY-RLGV-GALIVALIIAIV-VWTIAYIEYRKLLRQRRIDWLIERIRERAEDSGNESDGDHEELSTMVD--MG--HLRLLDVNDL*------- : 86 
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C.ZA.2003. : MLNL--LARV-DY-RLGV-GALIVALIIAIV-VWTLVYIEYRKLLRQRKIDWLIKRIRERAGDSGNESDGDHEELSTMVD--MG--HLRLLDVNDL*------- : 86 
C.IL.1998. : MVDLLDL--LEKV-DY-RLAV-IALIVVAIITIV-VWTIVYIEYRKLLRQRKIDRLIERIRERAEDSGNESEGDAEELSTMVE--MG--NLRLLDVADL*---- : 89 
C.IL.1999. : MLEF--LEIV-DY-RITV-GAFIVALIIAIV-VWTIAYIEYRKLSRQRKIDRLIERIRERAEDSGNESDGDADELATMVD--MG--NLRLMDVVDL*------- : 86 
C.DJ.1991. : MIDL--LAKV-DY-RLAV-AAFIIAFIIAIV-VWTIAYIEYRKLLRQRKIDRLIERIRERAEDSGNESDGDTDELSTMVD--RG--NLRLLDAVDV*------- : 86 
C.FI.1991. : MVDL--LAKV-DY-RLAI-GALIVALIIAIV-VWTIVYIEYRKLLRQRKIDWLVERIRERAEDSGNESEGDTEELSTMVE--MG--NLRLLDVIDL*------- : 86 
C.BW.1998. : MLEL--LEKV-DY-KITV-AAFIVALIIAIV-VWTIAYIEYRKLLRQRKIDCLIKRIRERAEDSGNESDGDTEELSTMVD--MG--NLRLLDANDL*------- : 86 
C.ZA..99ZA : MVDL--LAQV-DY-RIAV-GAFIVALIIAIV-VWTIVYIEYRKLLRQRKIDWLIKRIRERAEDSGNESEGDTEELETMVD--MG--NLRLLDVNDL*------- : 86 
C.ZA.2005. : ------------------------------------------------------MRVMGIQRNCQQWW--IWG--ILGFWMLMIC------------------- : 27 
C.ET.1986. : MVDL--LAKV-DY-RIVI-VAFIVALIIAIV-VWTIAYIEYRKLLRQRRIDRLIKRTRERAEDSGNESDGDTEELSTMVD--MG--NLRLLDVNDL*------- : 86 
C.UG.1990. : MLNL--LAGV-DY-RIGI-GALLIALIIAIV-VWIIVYIEYRKLLKQRRMDRLIKRIRERAEDSGNESDGDTEELSTMVD--MG--NLRLLDINDL*------- : 86 
C.ZA.2003. : MLEL-----L-DY-SLGV-GALIVALIIAIV-VWTIVYIEYRKLLRQKKIDQLIKRIRERAEDSGNESDGDTEELATMVD--VG--HLGLLDVADL*------- : 83 
C.DJ.1991. : MIDL--PAKV-DY-RLAV-GALIVALIIAIV-VWTIVYIEYRKLLRQRQIDWLIERIRERAEDSGNESDGDTEELATVVG--MG--NLRLLDVVDL*------- : 86 
C.IL.1999. : MLDL--LVRV-DY-RLGV-GALIVALIIAIV-VWTIAYLEYRKLLRVQKIDRLIKRIRERTEDSGNESDGDTEELATMVD--VG--HLRLLDAIDL*RE----- : 88 
C.ZA.2004. : MLGL--LAKV-DY-RLGI-GALIVALIIAIV-VWTIAYIEYRKWVRQEKINWLIKRIRERAEDSGNESDGDTEELSTMVD--MG--HLRLLDANDL*------- : 86 
C.ZA.2004. : MLDL--LAKV-DY-RVGV-GALIVAIIIAIV-VWTIAYIEYRKWVRQEKINRLIKRIRERAEDSGNESDGDAEELSTMVD--MG--HLRLLDVNDL*------- : 86 
C.ZA.2005. : MIDL--LTKV-DY-RLGV-GAFIVALIIAIV-VWTIAYLEYRKWARQKKIDRLIERVRERAEDSGNESDGDTEELAAMGD--MG--HLRLLAVNDL*------- : 86 
C.IN.1993. : MID------L-DY-RLGV-GALIVALIIAIV-VWTIVYIEYRKLVRQSKINWLIKRIRERAEDSGNESEGDTEELSTMVD--MG--RLRLLDVNDL*------- : 82 
C.IN.1994. : MLD------L-DY-KLGV-GALIVALIIAIV-VWTIVYIEYRKLVKQRKINWLIERIRERAEDSGNESEGDTEELSTMVD--MG--RLRLLDINDL*------- : 82 
C.MM.1998. : MLD------L-DY-TLAV-GALIVALIIAIV-VWTIVYIEYRRLVNRKNRDWLLKRIRERAEDSGNESEGDTEELSTMVD--MG--R*GFW-C*EL*------- : 79 
C.IN..3007 : MLD------L-DY-KLGV-GALIVALIITIV-VWTIVYIEYRRLVNQRKIDWLIKRIRERAEDSGNESEGDTEELSTMVD--MG--RLRLLDVNDL*------- : 82 
C.IN.1993. : MLD------L-DY-KLGV-GALIVALIIVIV-VWTIVYIEYRRLVKQRKIDWLIKRIRERAEDSGNESEGDTEELSTMVD--MG--RLRLLDVNDL*------- : 82 
C.IN.1993. : MLD------L-DY-KLAV-GALIVALIIAIV-VWIIAYIEYRKLVKQRKIDWLIKRIRERAEDSGNESEGDTEELSTMVD--MG--RLRLLDVNDL*------- : 82 
C.TW..TWC4 : MLD------L-DY-KLAV-GALIVALIIAIV-VWTIAYIEYRKLVKQRKIDWLIKRIRERAEDSGNESEGDTEELSTMVD--MG--RLRLLDVNDL*------- : 82 
C.IN..4051 : MIG------L-DY-KLAV-GALIVALIIAIV-VWTIVYIEYRRLVKQRKIDWLIKRIRERAEDSGNESEGDTEELSTMVD--MG--RLRLLDVNDL*------- : 82 
C.IN..2994 : MLE------L-DY-KLGV-GALIVALIIAIV-VWIIVYIEYRRLVKQRKIDWLIKRIRERAEDSGNESEGDTEELSTMVD--MG--RLRLLDVNDL*------- : 82 
C.IN.1998. : MLD------L-DY-RLAV-GALIVALIIAIV-VWIIVYIEYRKLVKQRKIDQLIKRIRERAEDSGNESKGDTEELSTMVD--MG--NLRLLDVNEL*------- : 82 
C.IN..4938 : MLD------L-DY-RLAV-GALIVVLIIAIV-VWTIVYIEYRRLVQQRKIDWLIKRIRERAEDSGNESEGDTEELSTMVD--MG--RLRLLDVNDL*------- : 82 
C.IN..1038 : MLD------L-DY-KLAV-GALIVALIIVIV-IWTIVYLEYRKLVKQRKIDRLIERIRERAEDSGNESDGDTEELSTLVD--MG--NLRLLDVNDL*------- : 82 
C.IN..1106 : MFD------L-DY-KIVV-GAFVVALIIAII-VWTIVYIEYRRLKKQRKIDRLIERIRERAEDSGNESEGDTEELSTMVD--MG--RLRLLDANDL*------- : 82 
C.IN..4107 : MLN------L-DY-KVVV-GALIAALIIAIV-VWTIAYIEYRKLVEQRKIDRLIERIRERAEDSGNESDGDTEELSTMVD--MG--RLRLLDVNDL*------- : 82 
C.IN..1038 : MLN------L-DY-KLAV-AAFILALIIAIV-VWTIVYIEYRKLIKQRKIDWLIERIRERAEDSGNESEGDTEELSTMVD--ME--RLRLLDVDDL*------- : 82 
C.TW..TWC1 : MID------L-DY-KLGV-GALIVALIIVIV-VWTIVYIEYRKLVRQRKIDWLIERIRERAEDSGNESEGDTEELSTMVD--MG--HLRLLDVNDL*------- : 82 
C.IN..3007 : MLD------L-DY-KLGV-GALIVALIIVIV-VWTIVYIEYRKLLRQRKIDWLVKRIRERAEDSGNESEGDTEELSTMVD--MG--HLRLLDVNDL*------- : 82 
C.IN..1038 : MSD------L-DY-KLAV-VALIVALIIAIV-VWTIAYIEYRKLLKQRKIDWLIERIRERAEDSGNESEGDTEELSTMVD--MG--RLRLLDVNDL*------- : 82 
C.IN.1998. : MLD------L-DY-KLAV-GAFIVALLIAIV-VWTIVFIEYRKLLRQRKIDWLIKRIRERAEDSGNESEGDTEELSTMVD--MG--HLRLLDVNDL*------- : 82 
C.IN..1106 : MVD------L-DY-KLTV-GAFVVALIIAIV-VWTIVFIEYRKLLRQRKIDRLIKRIRERAEDSGNESEGDTEELSTLVD--MG--NLRLLDANDL*------- : 82 
C.IN.2003. : MLD------L-NY-KLTV-GAFVIALILAIV-VWTIVYIEYRKLVRQRKIDRLIERIRERAEDSGNESGGDTEELPTLVD--MG--NLRLLDVHDL*------- : 82 
C.BW.2000. : MLD------L-DY-KVAV-GAFTVALILAIV-VWILVYREYRKLLRQKRIDNLIKRIRERAEDSGNESDGDTEELSTLVD--MG--NLRLL--DDL*------- : 80 
C.IN..2994 : MLE------L-DY-KIAV-GALIVALIIAIV-VWTIVYIEYRKLLRQKRIDRLIERIRERAEDSGNESEGDTEELSTMVD--MG--HLRLLAVNNL*------- : 82 
C.IN.1993. : -------------------------------------------------------MRVRGILRNYQQWW--IWG--ILGFWMLMIC------------------ : 27 
C.IN..4081 : ------------------------------------------------------MRVRGILRNYQQWW--IWG--VLGFWMLMSC------------------- : 27 
C.IN..1106 : ------------------------------------------------------MRVRGILRNYQHWW--IWG--ILGFWMLMIY------------------- : 27 
C.IN.1999. : MSWN------L-DY-KLAV-GALIIALIIAIV-VWTIVYIEYRRLVRQKKIDWLIKRIRERAEDSGNESEGDTEELSTMVD--MG--NLRLLDVNDL*------ : 83 
C.IN.1999. : MSWN------L-DY-KLAV-GALIIALIIAIV-VWTIVYIEYRRLVRQKKIDWLIKRIRERAEDSGNESEGDTEELSTMVD--MG--NLRLLDVNDL*------ : 83 
C.IN.1999. : MSWN------L-DY-KLAV-GALIIALIIAIV-VWTIVYIEYRRLVRQKKIDWLIKRIRERAEDSGNESEGDTEELSTMVD--MG--NLRLLDVNDL*------ : 83 
C.IN.1999. : MSWN------L-DY-KLAV-GALIIALIIAIV-VWTIVYIEYRRLVRQKKMDWLIKRIRERAEDSGNESEGDTEELSTMVD--MG--NLRLLDVNDL*------ : 83 
C.IN.1994. : M------L-DL-KLAV-GALIVALIIAIV-VWTIVYIEYRRLVKQRKIDWLIKRIRERAEDSGNESEGDTEELSTMVD--MG--RLRLLDVNDL*--------- : 80 
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C.ZA.1997. : MRD------L-T--ALGV-GALIVALIIVII-VWTIVYIEYKKLVRQKRIDWLIERIRERAEDSGNESDGDTEELSTMVD--MG--HLRLLDVNDL*------- : 81 
C.ZA..99ZA : MLN------L-L--AIGV-GAFIVALIIAIL-VWTIVYIEYRKLVKQRRIDWLVQRIRERAEDSGNESEGDTEELSTMVD--MG--HLRLLDGNDL*------- : 81 
C.IN..NARI : MLD------L-AS-ALAI-GALIVAAFIAIV-VWTIVYIEYRKLLRQRKIDQLIKRIRERTEDSGNESEGDVEELST?VD--MG--NLRLLDVNDL*------- : 81 
C.MM.1999. : MLE------I-DY-RLGV-GALIVALIIAII-VWTIVYIEYRKLVKQRKIDWLIERIRERAEDSGNESEGDTEELSTMVD--MG--RLRLLDVNEL*------- : 82 
C.CN.1998. : MLG------I-DY-RLGI-GALIVALIIAIV-VWTIVYIEYRRLVRQRKIDRLIKRIRERAEDSGNESEGDTEESSAMVD--MG--NLRLLDVNDL*------- : 82 
C.IN.1995. : MVN------L-DY-KLGV-GALIVALIIAIV-VWTIVYIEYRKLVQQRKIDWLIKRIRERAEDSGNESEGDTEELSTMVD--MG--RLRLLDVNDL*------- : 82 
C.IN..1106 : MLD------V-DY-RLGV-GALIVALIIAII-VWTIVYIEYRKLVQQRKIDWLIKRIRERAEDSGNESEGDTEELSTMVD--MG--RLRLLDVNDL*------- : 82 
C.IN..4958 : ------------------------------------------------------MRVMGTLRNYQQWW--IWG--VLGFWMLMIC------------------- : 27 
C.IN..1106 : ------------------------------------------------------MRVRGTRRNYQQWW--IWG--ILGFWMLMIY------------------- : 27 
C.BW.2000. : MFALF----EV-DY-RLTI-G-AFIVALFLAIVVWTIAYLEYRKLVRQRRIDQLVKRIRERAEDSGNESDGDTEELSTMVD--MG--HLRLLDV-NDL*----- : 85 
C.KE.1998. : ML----AV-DY-RLTV-A-AFIVVLIIAIVVWIIAYIEYRKLLKQRRIDWLVKRIRERAEDSGNESDGDTEE?STMVD--MG--HLRLLDV-NDL*-------- : 81 
C.TZ.2002. : MVD-----SI-DY-RLTV-GAFIIAFIIAIV-VWIIAYIEYRKLVRQRKIDQLIKRLGERAEDSGNESDGDIEELSTMVD--MG--NLRLLDANNL*------- : 83 
C.TZ.2002. : MVDF----LE-DY-RLGV-GALIVALIIAIV-VWTIAYLEYRKLLRQRRIDQIIKRIRERAEDSGNESDGDTEELATMVD--MG--NLRLLDVNDL*------- : 84 
C.ZA.2004. : MVDF-------IV--IGV-GALIVAFIIAII-VWIIAYLEYRKLVKQRKIDWLVKRIGERAEDSGNESDGDTEELSAMVD--MG--YLRLLDANDV*------- : 81 
C.ZA.2003. : MLN------L-DY-KIAV-AALIVALIIAII-VWTIVYIEYRKLLRQRKIDWLIKRIRERAEDSGNESEGDAEELSTMVD--MG--HLRLLDDNEL*------- : 82 
C.ZA.2003. : MWELLDK-----I-DY-NIAV-AAFIVALIIAIV-VWIIVYIEYRKVVRQRKIDWLIKRIRERAEDSGNESEGDTEELSAMVD--MG--HLRLLDVNDL*---- : 86 
C.US.1998. : MLLE------V-DY-RIGV-AALIVALSIAIV-VWTIVYIEYRKLLRQRKIDWLVQRIRERAEDSGNESDGDTEELATMVD--MG--HLRLLDVDEL*------ : 83 
C.TZ.2002. : MLD------V-DY-RLGV-AALILALIIAIV-VWTIAYIEYRKLLKQRKIDWLIKRIRERAEDSGNESDGDTEELSTMVD--MG--HLRLLDVNEL*------- : 82 
C.BW.2000. : -----------------------------------------------------------MRVKGIQRNWPQWW--IWG--SLGFWMLMFY-------------- : 27 
C.ZA.2004. : MIDL-VA-KL-DY-RLGI-AAITVALFIAII-VWTIVYLEYRKLRRQRKIDLLIERIRERAEDSDNESEGDTEELATMAD--MG--*LRLLDVNDL*------- : 85 
C.ZA.2003. : ML-DL-DY-RIGV-GALVAALILVII-IWTIVYIEYKKLLKQRKIDWLIERIRERAEDSGNESEGDTEELATMVD--MG--HLRLSDVNDL*------------ : 82 
C.ZA.2005. : MV-TL-DY-NITI-AAFVVALIIAII-VWTIAYIEYRKLRKQRKIDRLIERIRERAEDSGNESEGDTEELATMVD--MG--QLRLLDVNDL*------------ : 82 
C.ZA.2001. : MISL-IE-KI-DY-RLAV-GALIVALIIAIV-VWTIVYLEYRKVVRQRKIDRLIERIRERAEDSGNESEGDTEELATMVD--MG--HLRLLDDNDL*------- : 86 
C.BW.2000. : MLDL-T--QI-GY-ELGI-GALIVALIIAIV-VWTIVYIEYRKVLRQRKIDRLIKRIRERAEDSGNESEGDIEELEAIVD--MG--HLRLLGINNL*------- : 85 
C.KE.1997. : M--SLLQSCAIIGLVVAIILAIVVWTIVGIEYKKLLKQKRIDRLIRRIR-ERAEDSGNESDGDTDELSKLVE--MG--NYDLGDDNNL*--------------- : 81 
C.KE.1997. : M--SLLQSCAIIGLVVAIILAIVVWTIVGIEYKKLLKQKRIDRLIRRIR-ERAEDSGNESDGDTDELSKLVE--MG--NYDLGDDNNL*--------------- : 81 
C.KE.1997. : M--SLLQSCAIIGLVVAIILAIVVWTIVGIEYKKLLKQKRIDRLIRRIR-ERAEDSGNESDGDTDELSKLVE--MG--NYDLGDDNNL*--------------- : 81 
C.KE.1997. : M--SLLQSCAIIGLVVAIILAIVVWTIVGIEYKKLLKQKRIDRLIRRIR-ERAEDSGNESDGDTDELSKLVE--MG--NYDLGDDNNL*--------------- : 81 
C.KE.1997. : M--SLLQSCAIIGLVVAIILAIVVWTIVGIEYKKLLKQKRIDRLIRRIR-ERAEDSGNESDGDTDELSKLVE--MG--NYDLGDDNNL*--------------- : 81 
C.KE.1997. : M--SLLQSCAIIGLVVAIILAIVVWTIVGIEYKKLLKQKRIDRLIRRIR-ERAEDSGNESDGDTDELSKLVE--MG--NYDLGDDNNL*--------------- : 81 
C.KE.1997. : M--SLLQSCAIIGLVVAIILAIVVWTIVGIEYKKLLKQKRIDRLIRRIR-ERAEDSGNESDGDTDELSKLVE--MG--NYDLGDDNNL*--------------- : 81 
C.KE.1997. : M--SLLQSCAIIGLVVAIILAIVVWTIVGIEYKKLLKQKRIDRLIRRIR-ERAEDSGNESDGDTDELSKLVE--MG--NYDLGDDNNL*--------------- : 81 
C.KE.1997. : M--SLLQSCAIIGLVVAIILAIVVWTIVGIEYKKLLKQKRIDRLIRRIR-ERAEDSGNESDGDTDELSKLVE--MG--NYDLGDDNNL*--------------- : 81 
C.KE.1997. : M--SLLQSCAIIGLVVAIILAIVVWTIVGIEYKKLLKQKRIDRLIRRIR-ERAEDSGNESDGDTDELSKLVE--MG--NYDLGDDNNL*--------------- : 81 
C.KE.1997. : M--SLLQSCAIIGLVVAIILAIVVWTIVGIEYKKLLKQKRIDRLIRRIR-ERAEDSGNESDGDTDELSKLVE--MG--NYDLGDDNNL*--------------- : 81 
C.KE.2001. : M-W??L?ICAIVGLIV??ILAIVVWTI?GIEYKKILKQRKI?RLI?RI?-ERAED????SDGDT?DLAALIE--MG--NYDLGIDNNL?--------------- : 68 
C.KE.2001. : M-W??L?ICAIVGLIV??ILAIVVWTI?GIEYKKILKQRKI?RLI?RI?-ERAED????SDGDT?DLAALIE--MG--NYDLGIDNNL?--------------- : 68 
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Figure F1: An alignment of the 644 HIV-1 subtype C Vpu amino acids sequences available from the Los Alamos sequence database. 
Sequences are compared to the top line. Dots represent identical residues, and variant residues are shown. The total length of the 
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